New App Brings Social Approach To Goal Setting

Personal goals are made more achievable than ever with the launch of new iOS app, Golsie (http://go.golsie.com/). Pegged as the ‘social network of achievement’ the free app offers a fun and engaging social platform to help ambitious users set goals, track progress and successfully complete objectives. The app is based around a three stage process of Define, Track and Share and Achieve. Define helps users create initial goals and allows for detailed descriptions, the setting of a target date, addition of a photo and adjustments to privacy settings. Track and Share brings a social aspect to the app which gives users a chance to add steps, questions and notes to the goal. It also encourages networking and communication with other Golsie users in order to find a community of inspirational friends and people with similar goals. Achieve is the final stage wherein goal setters become increasingly closer to reaching their goal and are eventually able to mark it as completed. The journey to goal completion is peppered with elements of fun, engagement and interaction and rewards users with points, badges and levels as they make progress. Friendly rivalry is encouraged, the app allowing users to compete with friends and fellow goal setters for an added element of motivation. Tom Malloy, Golsie Co-Founder said, “Golsie means no-one has to embark on goal setting alone. The fun and social interface ensures that goal setting and achievement is an interactive and enjoyable experience for everyone involved.” Golsie is also compatible with social networking platforms which let users to share their goals and accomplishments through sites such as Facebook. This further adds to the army of supporters and allows users to thrive off public encouragement and advice that is often essential to achieving difficult goals. The entire process is wonderfully social and gives users a chance to draw on the inspiration and encouragement of others when they need it the most. The Golsie database includes over 100,000 lifestyle, health, fitness, educational and career goals that have been developed with the help of a number of well-known advisors, behavioural scientists and coaches. The Madrid-based start up is gaining rapid popularity amongst smartphone users who wholeheartedly embrace the idea of embarking on a fun, social and interactive path to goal achievement. Golsie also gained industry recognition when it was selected to take part in Madrid based technological start-ups accelerator, Top Seeds Lab.   The Golsie app was developed at the IE Venture Lab at the International Centre for Entrepreneurial Management. The Golsie team is led by Tom Malloy, Denny Morawiak and Sriram Vaidhyanathan. The exciting new app is now available for free download from the Apple App Store (https://itunes.apple.com/WebObjects/MZStore.woa/wa/viewSoftware?id=716442528&mt=8). To find out more about Golsie visit: http://go.golsie.com. For an exclusive glimpse into the ever growing database of goals try out the interactive demo: www.golsiegoalinspiration.com (http://bit.ly/15XaxMP). Facebook: https://www.facebook.com/GolsieOfficial Twitter: https://twitter.com/@GolsieOfficial Tumblr: http://blog.golsie.com/

WORLD CHALLENGE OFFERS COMMUNITY SUPPORT

The global schools expeditions company, which has its head office in High Wycombe and works with schools in over 25 countries, paid a visit to Thames Valley Adventure Playground (TVAP) in Taplow, near Maidenhead on Friday (April 11) to help staff and other volunteers rebuild its Sensory Garden, situated in the middle of the 2.5 acre site. TVAP, a registered charity, has been operating since 1982 and provides a chance for children and adults with all types of special needs to enjoy the fun, freedom and friendship afforded by the opportunity to play and share experiences in a safe and stimulating environment, with users travelling from Berkshire, Buckinghamshire, Oxfordshire, London and beyond. World Challenge, part of TUI Travel Group PLC – the world’s largest leisure travel company, encourages all of its employees to take advantage of the TUI Discovery (charity) Day (on company time) each year. Group MD Matt Eastlake even donned his overalls for the day and was quick to praise the on-going efforts of the TVAP team. He said: “World Challenge’s ethos is all about challenge, participation and environment and that’s why we were delighted to be able to lend our support and in the process help make a real difference to the Playground, its users and the local community. “We plan expeditions abroad for over 10,000 students every year so hopefully our experience and knowledge ensured for a successful and rewarding day for everyone concerned. There were plenty of smiling faces which is the most important thing.” TVAP needs approximately £350,000 a year to stand any chance of surviving – a point reaffirmed by Donations Manager Nicky Hutchinson. She said: “We were absolutely delighted to have World Challenge’s help with our new Sensory Garden. Such assistance plays a crucial part in the development of the Adventure Playground, enabling us to continue to offer the most stimulating environment possible to our users and their families.  “With over 13,500 visits made to the Playground each year, the support of the local community is a key factor in providing opportunities for meaningful play for children and adults with all types of special needs - opportunities which most people would take for granted, but which can be so hard to experience if you have a disability.  “From all those for whom the Playground is such a lifeline; a huge thank you to everyone from World Challenge involved in the project - we couldn’t have done it without you!” For more information on TVAP or to donate visit: http://www.tvap.co.uk

Final data from the phase II COSMOS study with Simeprevir in combination with Sofosbuvir presented at EASL

Stockholm, Sweden — Medivir AB (OMX: MVIR) today announces that positive new simeprevir data were presented at The International Liver Congress™ 2014 of the European Association for the Study of the Liver (EASL) in London.The data presented included; · Final phase II data from the interferon-free COSMOS study · Phase III efficacy data in patients with genotype 4 hepatitis C · Subgroup analyses of patients from phase III studies QUEST-1, QUEST-2 and PROMISE Final phase II data from the interferon-free COSMOS study Cohort 2Final results from cohort 2 of the phase II COSMOS study demonstrated that 93 percent of prior null responder and treatment-naïve patients with genotype 1 HCV and advanced liver fibrosis (METAVIR scores F3 and F4) who were treated with simeprevir and sofosbuvir for 12 weeks achieved sustained virologic response 12 weeks after the end of treatment (SVR12). The addition of ribavirin did not improve SVR rates and consistent responses for both treatment arms were seen across HCV genotype subgroups after 12 weeks. +---------------------+-------------+-----------------------+|SVR12 Among Patient ||Subgroups with ||Genotype 1 HCV and ||Advanced Liver ||Fibrosis/Cirrhosis in ||Cohort 2 of the COSMOS ||Study* |+---------------------+-------------+-----------------------+|12 Weeks of Treatment |+---------------------+-------------+-----------------------+|Regimen |Simeprevir/So|Simeprevir/Sofosbuvir +|| |fosbuvir (%) |Ribavirin (%) |+---------------------+-------------+-----------------------+|Overall |93 |93 |+---------------------+-------------+-----------------------+|Genotype 1a HCV |88 |93 ||without the Q80K | | ||polymorphism | | |+---------------------+-------------+-----------------------+|Genotype 1a HCV with |100 |88 ||the Q80K polymorphism| | |+---------------------+-------------+-----------------------+|Genotype 1b HCV |100 |100 |+---------------------+-------------+-----------------------+|METAVIR F4 |86 |91 |+---------------------+-------------+-----------------------+        *Excluding non-virologic failures. The most common adverse events reported during the study were fatigue, headache, nausea, anemia, pruritus, dizziness, rash and photosensitivity. One patient discontinued treatment due to adverse events. Cohort 1Previously presented data from cohort 1 at AASLD in November 2013, demonstrated that 96 percent and 93 percent of prior null responder patients with METAVIR F0-F2 scores treated with simeprevir and sofosbuvir without or with ribavirin, respectively, for 12 weeks achieved SVR12. +-------+-------------+---------------------------------+|SVR12 ||Among ||Patient ||Subgroups ||with ||Genotype ||1 HCV and ||METAVIR ||Scores of ||F0-F2 in ||Cohort 1 ||of the ||COSMOS ||Study* |+-------+-------------+---------------------------------+|12 Weeks ||of ||Treatment |+-------+-------------+---------------------------------+|Regimen|Simeprevir/So|Simeprevir/Sofosbuvir + Ribavirin|| |fosbuvir (%) |(%) |+-------+-------------+---------------------------------+|Overall|96 |93 |+-------+-------------+---------------------------------+|METAVIR|100 |94 ||F2 | | |+-------+-------------+---------------------------------+        *Excluding non-virologic failures. In genotype 1a patients with the Q80K polymorphism at baseline, 83 percent and 89 percent achieved SVR12 after 12 weeks of treatment without and with ribavirin, respectively. The most common adverse events reported during the study were fatigue, headache, nausea and insomnia. Two patients discontinued treatment due to adverse events. Phase III efficacy data in patients with genotype 4 hepatitis C Results from the Phase III RESTORE trial of simeprevir in combination with pegylated interferon and ribavirin in HCV genotype 4 treatment-naïve and treatment-experienced patients demonstrated that overall 65 percent of patients achieved SVR12, including 83 percent of treatment-naïve patients, 86 percent of prior relapsers, 60 percent of prior partial responders, and 40 percent of prior null responders. Among patients with more severe liver fibrosis characterized by a METAVIR score of F3 or F4, 67 percent and 47 percent achieved SVR12, respectively. Among patients with genotype 4a and 4d HCV, 69 percent and 52 percent achieved SVR12, respectively. The most frequent adverse events included influenza-like illness, asthenia (weakness) and fatigue. Genotype 4 HCV is considered particularly difficult to cure and currently only limited treatment options are available. Subgroup analyses of patients from phase III studies of Simeprevir Analyses of pooled efficacy data from the QUEST-1 and QUEST-2 studies found 87 percent of European patients treated with simeprevir in combination with pegylated interferon and ribavirin achieved SVR12, compared to 80 in the overall study population. In an analysis from the PROMISE study, 88 percent of European patients treated with simeprevir in combination with pegylated interferon and ribavirin achieved SVR12 compared to 79 percent in the overall study population. The efficacy of simeprevir in combination with pegylated interferon and ribavirin was also observed among European patients with baseline characteristics typically considered more difficult to cure. In QUEST-1 and QUEST-2, 71 percent of patients with METAVIR F4 scores, 86 percent of patients with the IL28B CT genotype, 69 percent of patients with the IL28B TT genotype and 64 percent of genotype 1a patients with the Q80K polymorphism at baseline achieved SVR12 in the simeprevir arm, compared to 25 percent, 44 percent, 31 percent and 50 percent of patients in the active placebo arm, respectively. In PROMISE, 85 percent of patients with METAVIR F4 scores, 88 percent of patients with the IL28B CT genotype, 77 percent of patients with the IL28B TT genotype and 75 percent of genotype 1a patients with the Q80K polymorphism at baseline achieved SVR12 in the simeprevir arm, compared to 30 percent, 41 percent, 18 percent and 57 percent of patients treated in the active placebo arm, respectively. For more information please contact: Rein Piir, EVP Corporate Affairs & IR, mobile: +46 708 537 292 Medivir is required under the Securities Markets Act to make the information in this press release public. The information was submitted for publication at 17.15 CET on 12 April 2014. About Simeprevir Simeprevir is an NS3/4A protease inhibitor jointly developed by Janssen R&D Ireland and Medivir AB and indicated for the treatment chronic hepatitis C infection in combination with pegylated interferon and ribavirin in HCV genotype 1 and 4 infected patients with compensated liver disease, including cirrhosis. Janssen is responsible for the global clinical development of simeprevir and has exclusive, worldwide marketing rights, except in the Nordic countries. Medivir AB retains marketing rights for simeprevir in these countries under the marketing authorization held by Janssen-Cilag International NV. Simeprevir was approved for the treatment of chronic hepatitis C infection as part of an antiviral treatment regimen in combination with pegylated interferon and ribavirin in genotype 1 infected adults with compensated liver disease, including cirrhosis in September 2013 in Japan, in November 2013 in Canada and the U.S. and in March 2014 in Russia. A Marketing Authorisation Application was submitted to the European Medicines Agency (EMA) in April 2013 by Janssen-Cilag International NV seeking approval of simeprevir for the treatment of genotype 1 or genotype 4 chronic hepatitis C and the Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion, recommending Marketing Authorisation in the European Union for the use of simeprevir in combination with other medicinal products for the treatment of chronic HCV. This application is under review by the EMA. About Medivir Medivir is an emerging research-based pharmaceutical company focused on infectious diseases. Medivir has world class expertise in polymerase and protease drug targets and drug development which has resulted in a strong infectious disease R&D portfolio. The Company’s key pipeline asset is simeprevir, a novel protease inhibitor for the treatment of hepatitis C that is being developed in collaboration with Janssen R&D Ireland. The company is also working with research and development in other areas, such as bone disorders and neuropathic pain. Medivir has also a broad product portfolio with prescription pharmaceuticals in the Nordics.

Importation of softwood logs to Sweden reached a 10-year high in 2013 with Norway and Latvia being the major suppliers of both pulplogs and sawlogs

Seattle, USA. Sweden is the fourth largest importer of logs in the world, despite having forests that cover almost two-thirds of the country. The import volumes have been growing steadily the past five years, with 2013 imports being almost 60 percent higher than five years ago. Softwood logs make up all of the increase in imports and Wood Resource Quarterly (WRQ) reported that 2013 had the highest softwood log import volume over the past ten years. In a contrary development, the importation of hardwood logs in 2013 declined, with import volumes being down about 16 percent from the previous year. As a matter of fact, imports last year fell to the second lowest level in 15 years, with Latvia reducing shipments the most. During the past few years, between 10-15% of the imported log volume have been sawlogs destined for sawmills in the Southern part of Sweden, of which most have been sourced in Norway.  Almost 90% of imported logs in 2013 were pulplogs, evenly split between softwood and hardwood. The two major supplying countries have been Norway (softwood) and Latvia (softwood and hardwood), with other neighboring countries including Finland, Russia and Estonia following far behind. The total softwood log shipments from Norway to Sweden, including sawlogs and pulpwood, reached just over two million m3 in 2013, up from 1.4 million m3 in 2012 and only 709,000 m3 in 2011. The major reason for this dramatic increase was that the Swedish pulp company Sodra permanently closed its pulpmill in Tofte, Norway last summer. As a consequence, private forest owners in the region have increased their log shipments to pulp mills in central Sweden. This has had an impact on log flows and prices in the local markets in Sweden and there has been no shortage of wood fiber in this part of the country, according to the WRQ (www.woodprices.com). Imported wood-raw material for the Swedish forest industry is not just a marginal business but quite important for many manufacturers of lumber and pulp. The past two years, imported logs have accounted for about ten percent of the total log consumption in the country, this was up from 7.5 percent in 2009.   Global pulpwood and timber market reporting is included in the 52-page quarterly publication Wood Resource Quarterly (WRQ). The report, established in 1988 and with subscribers in over 30 countries, tracks sawlog, pulpwood, lumber and pellet prices, trade and market developments in most key regions around the world. To subscribe to the WRQ, please go to www.woodprices.com

H&M teams up with Alexander Wang for their next design collaboration

The New York based Fashion Designer’s eponymous brand has firmly established itself by perpetually evolving and re-contextualizing the urban uniform, since it was launched on the runway in 2007. Alexander Wang’s core sensibility is a reflection on contrasts, blending seamlessly between the refined and the imperfect. His collections have an unprecious outlook on fashion, and always reflect a sense of ease. The Alexander Wang x H&M collection will feature apparel and accessories for women and men. Typical for his irreverent approach, Alexander Wang will propose a new take on the lifestyle product offering that goes beyond fashion. The full collection will be available in 250 H&M stores worldwide, and online starting November 6, 2014. Alexander Wang says, “I am honored to be a part of H&M’s designer collaborations. The work with their team is an exciting, fun process. They are very open to push boundaries and to set a platform for creativity. This will be a great way for a wider audience to experience elements of the Alexander Wang brand and lifestyle.” "Alexander Wang is one of the most important voices in fashion today. He understands exactly what people want to wear and does it with an energy and passion that’s infectious. It feels incredible to be collaborating with him this year,” says Margareta van den Bosch, H&M’s creative advisor. #ALEXANDERWANGxHMwww.alexanderwang.comwww.hm.com/press

Sun shines on York Minster's Palm Sunday Procession

The sun shone this morning (13 April 2014) as the choir, clergy and congregation walked from St Helen's Square to York Minster, following Joey the Donkey. The Palm Sunday procession marks the start of York Minster's Holy Week.  The procession left St Helen’s Square at 10am, recalling the entry of Jesus into Jerusalem, days before he is arrested and crucified and one week before he rose from the dead on Easter Sunday (20 April).  Holy Week is one of the busiest times of the year for York Minster, which is the only cathedral in the country to host daily Choral Evensong from Palm Sunday every day until Easter Sunday.  Additional services take place throughout the week to reflect the solemnity of the days leading up to Christ’s crucifixion, marked on Good Friday. On the evening of Easter Saturday (19 April) preparations begin for the Easter celebrations, including the Easter Vigil.  This unique service takes place in darkness in the space beneath York Minster’s central tower, and sees cloths and remaining oil from the year’s services burnt, before a new candle is lit. Following the Service of Light and Service of Lessons (a series of readings) those present then move to the Crypt, where baptisms and confirmations take place by candlelight, in advance of the first Easter Communion. Easter Sunday traditionally hosts one of the busiest services of the year, Solemn Eucharist at 10.00am, which features the full York Minster Choir and at which the Archbishop of York will preside and preach. Throughout Holy Week, visitors to York Minster will see the Easter Garden, located beneath the Five Sisters Window in the North Transept.  A bare cross hangs beneath the central tower, which is draped with a white cloth ready for the Easter Sunday service – a procedure that will be familiar to those who watched the recent BBC1 Yorkshire series, The Minster. A host of activities for families and children are also planned for Holy Week, including Little Explorer Backpacks and trail sheets for children, and Easter trails for adult visitors.  Revealing York Minster in the Undercroft – the cathedral’s latest visitor attraction which is soon to celebrate its first full year of opening – will be open throughout the week, allowing visitors to explore 2000 years of history through interactive underground chambers. Visitors will also be able to explore The Orb in the East End of the Minster and see the latest conserved panel of medieval stained glass taken from the Great East Window, which depicts an angel pruning vines, with horses outside the raised portcullis of a walled city. For more information on services, events and activities at York Minster over the Easter period, please visit www.yorkminster.org ENDS For further media information or photographs, please contact: Jay Commins Pyper York Limited Tel:         01904 500698 Email:    jay@pyperyork.co.uk

Hexagon to Acquire Mintec, Software Developer and Service Provider for the Mining Industry

Hexagon AB, a leading global provider of design, measurement and visualisation technologies, has as of today entered into an agreement to acquire Mintec Inc., a resource modelling, optimisation, mine planning and scheduling software developer for the mining industry. Headquartered in Tucson, AZ, USA, Mintec has with its 232 employees grown into a global network of mining professionals providing technology, service and support in some of the most complex mining operations around the world. MineSight, the company’s modeling and mine planning brand since 1970, is well-known and respected in the industry. Mining is becoming a more precise practice, and accurate mine planning and scheduling is at the forefront of this change. Hexagon has been active primarily in the operations domain, but the integration of the planning, scheduling and daily production capabilities of Mintec will enable Hexagon to close the loop and control data flow from design and mine planning through extraction and back into life- of-mine planning, providing a comprehensive flow of data across all mining operations. “The acquisition of planning and scheduling software strengthens our mining solution strategy, providing a platform for comprehensive life-of-mine solutions,” said Hexagon President and CEO Ola Rollén. “The combination of proven technologies from Leica Geosystems, Devex, SAFEmine and now Mintec, in connection with our geospatial product suite and computer-aided dispatch solutions from Intergraph, we have the tools and technologies to leap ahead of the competition, giving Hexagon a unique position in the market.” The transaction remains subject to customary closing conditions. Closing is expected to be effected no later than June 2014.

Notice of Annual General Meeting in Moberg Pharma AB (publ)

Attendance at the Annual General Meeting Shareholders who wish to participate in the Annual General Meeting must:-       Be recorded in the share register maintained by Euroclear Sweden AB (“Euroclear”), on Wednesday, May 7, 2014, and-   Give notice of attendance to the Company under address: Moberg Pharma AB (publ), Gustavslundsvägen 42, 5 tr, 167 51 Bromma, att. Anna Ljung or by e-mail to anna.ljung@mobergpharma.se, at the latest on Wednesday, May 7, 2014 at 4:00 p.m. When giving notice of attendance, shareholders must state their name, civil registration number or corporate registration number, address, telephone number and, where applicable, number of accompanying assistants (no more than two). Shareholders can participate and vote at the Meeting personally or by proxy. Shareholders whose shares are registered in the name of a nominee must, in order to be entitled to participate in the Annual General Meeting, with the help of the nominee, re-register their shares in their own names in the share register maintained by Euroclear, so that they are registered on Wednesday, May 7, 2014. Shareholders represented by proxy should submit a power of attorney in original, along with other authorization documents, when giving notice of attendance to the Annual General Meeting. A power of attorney may be valid for up to five years from issuance. The Company provides forms of power of attorney on the Company´s website www.mobergpharma.se. Representatives of legal persons must present a copy of the legal person’s certificate of registration or other equivalent document demonstrating the right to act on behalf of the legal person. Number of shares and votesAs per the date of this notice, there are a total of 11,893,572 shares and votes in the Company. The Company holds no own shares. Proposed agenda 1. Opening of the Meeting 2. Election of Chairman of the Meeting 3. Preparation and approval of the voting list 4. Election of one or two persons to verify the minutes 5. Determination whether the Meeting has been duly convened 6. Approval of the agenda 7. Presentation of the annual report and the audit report as well as the consolidated accounts and the consolidated audit report 8. Speech by the Chief Executive Officer, Peter Wolpert 9. Resolutions on:a) Adoption of the income statement and the balance sheet, as well as the consolidated income statement and the consolidated balance sheetb) Allocation of the Company’s result according to the adopted balance sheetc) Discharge from liability of the Board members and the Chief Executive Officer10. Determination of the number of Board members and deputy members11. Determination of fees to the Board of Directors and Auditors12. Election of the Board of Directors and Chairman of the Board of Directors13. Proposal for resolution on principles for establishing the Nomination Committee and its work14. Proposal for resolution on principles for remuneration of senior executives15. Proposal for resolution on Employee Stock Option Plan 201416. Proposal for resolution regarding authorization for the Board of Directors to issue new shares17. Closing of the Meeting Proposals for resolution Election of Chairman of the Meeting (Item 2)The Nomination Committee of the Company, consisting of Per-Olof Edin, Chairman of the Nomination Committee, representative of Östersjöstiftelsen, and the members Henrik Blomquist, representative of Bure Equity AB (publ), Håkan Åström, representative of SIX SIS AG, and Mats Pettersson, Chairman of the Board of Directors, proposes that Mats Pettersson be elected as Chairman of the Annual General Meeting. Resolution on allocation of the Company’s result according to the adopted balance sheet (Item 9.b) The Board of Directors proposes that no dividend should be paid for the fiscal year 2013. Election of the Board of Directors and Chairman of the Board of Directors and determination of fees to the Board of Directors and Auditors (Items 10, 11 and 12)The Nomination Committee proposes that the Board of Directors shall consist of six (6) persons and no Deputies. The Nomination Committee proposes re-election of Mats Pettersson, Wenche Rolfsen, Torbjörn Koivisto, Geert Cauwenbergh and George Aitken-Davies for a term of office extending until the end of the next Annual General Meeting, while Peter Wolpert, Gustaf Lindewald and Peter Rothschild have declined re-election and, thus, resign as board directors. In consultation with Peter Wolpert the Nomination Committee has found it principally more correct to refine his capacity at the Board Meetings, and that he will therefore only attend as CEO and not as board director. Further, the Nomination Committee has proposed to also appoint Thomas B. Thomsen as a Board Director. In addition, the Nomination Committee proposes re-election of Mats Pettersson as Chairman of the Board of Directors. Thomas B. Thomsen has a broad international experience from senior positions within the pharmacy industry with focus on OTC products, inter alia as Managing Director of marketing companies within Pfizer and Johnson & Johnson, Senior Vice President for OTC products within Reckitt Benckiser and Global Head of Category at Novartis Consumer Health. Thomas B Thomsen is a Board Director of Cederroth AB (Sweden) and Symprove PLC (England). The Nomination Committee proposes an aggregate fee to Board members of SEK 1,000,000, of which SEK 300,000 to the Chairman, SEK 250,000 to the Deputy Chairman and SEK 150,000 per member elected by the Annual General Meeting with the exception of George Aitken-Davies. It is noted that at the 2011 Annual General Meeting the auditing firm Ernst & Young AB was appointed as the Company’s Auditor. It is noted that the authorized public accountant Björn Ohlsson was appointed as Chief Auditor. The mandate runs until the end of the 2015 Annual General Meeting. The Nomination Committee proposes that fees to the Auditors, for a period until the end of the 2015 Annual General Meeting, are to be paid as per approved invoice. Proposal for resolution on principles for establishing the Nomination Committee and its work (Item 13)             The Nomination Committee proposes that the Annual General Meeting resolves on a Nomination Committee in accordance with the following principles. The Annual General Meeting assigns the Chairman of the Board of Directors to contact the three largest shareholders in term of votes or owner groups (hereby referred to both directly-registered shareholders and nominee-registered shareholders), according to a transcript of the share register maintained by Euroclear Sweden AB as per September 30, 2014, each appointing a representative to, besides the Chairman of the Board of Directors, constitute the Nomination Committee for the period until a new Nomination Committee is appointed by mandate from the next Annual General Meeting. If any of the three largest shareholders or owner groups declines to elect a representative, the fourth largest shareholder or owner group will be asked, and so on, until the Nomination Committee consists of four members. The majority of the members of the Nomination Committee are to be independent of the Company and its executive management. At least one member of the Nomination Committee is to be independent of the Company´s largest shareholder in term of votes, or any group of shareholders that act in concert in the governance of the Company. Neither the Chief Executive Officer nor other members of the executive management are to be members of the Nomination Committee. Board members may be members of the Nomination Committee but may not constitute a majority thereof. If more than one Board member is on the Nomination Committee, no more than one of these may be dependent of a major shareholder in the Company. The Nomination Committee appoints Chairman within the Committee. Neither the Chairman of the Board of Directors nor any other Board member may be Chairman of the Nomination Committee. The names of the members of the Nomination Committee shall be announced no later than six months prior to the 2015 Annual General Meeting. In the event that one of the members of the Nomination Committee resigns before the Committee´s work is completed and if the Nomination Committee is of the opinion that there is a need to replace the member, the Nomination Committee shall appoint a new member according to the principles above, but based on a transcript of the share register maintained by Euroclear Sweden AB, as soon as possible after the member has resigned. A change in the composition of the Nomination Committee shall be announced immediately. No fees shall be paid to the members of the Nomination Committee for their work in the Nomination Committee. The Nomination Committee shall submit proposals on the following issues for resolution by the 2015 Annual General Meeting: a)    Proposal for Chairman of the Meetingb)    Proposal for the Board of Directorsc)    Proposal for Chairman of the Board of Directorsd)    Proposal for fees to the Board of Directors, with distribution between the Chairman and other Board memberse)    Proposal for Auditorsf)     Proposal for fee to Company Auditorsg)    Proposal for principles for establishing the Nomination Committee for the 2016 Annual General Meeting. Proposal for resolution on principles for remuneration of senior executives (Item 14)The Board of Directors proposal for resolution on principles for remuneration of senior executives is consistent with previous years´ principles for remuneration and is mainly based on existing contracts between the Company and senior executives. The Board of Directors proposes that the Meeting resolves to adopt principles for remuneration of senior executives on the following terms: Moberg Pharma shall offer a total compensation at market rate that enables for qualified senior executives to be recruited and retained. The compensation paid to the Chief Executive Officer and other senior executives may consist of basic salary, variable compensation, other benefits and pension benefits. The total compensation is based on the basic salary and must be proportionate to the executive’s responsibilities and authority. Variable compensation is capped at 25 - 50 per cent of each executive’s basic annual salary and is based on results achieved in relation to individually defined qualitative and quantitative targets as well as the Company´s result in relation to goals set by the Board of Directors. Pensionable salary comprises only of basic salary. To the extent that Board members perform work for the Company or any other Group Company, besides work in the Board of Directors, consultancy fee at market rate may be paid. The notice period shall be at least three months if the senior executive takes the initiative and if the Company takes the initiative between three and twelve months. Severance is not paid. The Meeting shall, when applicable, decide on all share and share-price related programs. Allotment shall be made in accordance with the resolution of the Shareholders’ Meeting. With the exception of the employee stock options allotted and accrued, and what is provided for under existing employment contracts as referred to above, senior executives are not entitled to any benefits after the termination of the employment/assignment. The Board of Directors shall be entitled to deviate from the above mentioned principles for remuneration of senior executives if there are special reasons. Proposal for resolution on Employee Stock Option Plan (Item 15)The Board of Directors proposes that the Annual General Meeting (i) resolve to adopt an employee stock option plan for 2014 for employees in the Company and in the Company’s wholly-owned subsidiary Moberg Pharma North America LLC (”Moberg North America”), (ii) resolve on issue of warrants to the Company’s wholly-owned subsidiary Moberg Derma Incentives AB, reg. no. 556750-1589, (”Incentives”) for the fulfillment of the Company’s commitments under the employee stock option plan, and (iii) approve transfer of warrants or shares in the Company to employees in the Company and Moberg North America. (i) Employee Stock Option Plan 2014The Board of Directors proposes that the Annual General Meeting resolves to adopt Employee Stock Option Plan 2014 on principally the following terms: The Board of Directors and the Chief Executive Officer are entitled to, within the scope of the employee stock option plan, resolve on allotment of maximum 213, 500 employee stock options to key personnel in the Company and Moberg North America. It will be permissible to allot a maximum of 50,000 employee stock options per plan participant. The Board of Directors and the Chief Executive Officer shall decide which persons shall be encompassed by the Employee Stock Option Plan based on position, qualification and individual performance. The maximum allotment may be adjusted proportionally based on each person's time as an employee in the Company. The employee stock option plan will include the following senior executives in the Company; Anna Ljung, Kjell Rensfeldt, Martin Ingman, Peter Wolpert and Steve Cagle. The three first mentioned are proposed to be allotted 15,000 employee stock options each and the two last mentioned are proposed to be allotted 50,000 employee stock options each. Participants in the employee stock option plan shall be allotted the employee stock options free of charge. The allotment of employee stock options will take place immediately, in connection with the 2014 Annual General Meeting. Each employee stock option shall entitle the holder to subscribe for one (1) new share in the Company at a subscription price equivalent to 110 per cent of the volume-weighted average price paid for a share in the Company on the NASDAQ OMX Stockholm during ten trading days following the 2014 Annual General Meeting, however never less than the share quotient value. The employee stock options can be used for subscription of new shares from June 30, 2017 until December 31, 2018. The employee stock options are linked to employment in the Company. The employee stock options will be cancelled if the employment in the Company is terminated and the employee at that time had not earned them. The employee stock options earned by the employee before the time of termination shall be used for subscription no later than six months thereafter. The employee stock options are non-transferable. In view of the above proposed terms, the size of the allotment and other circumstances, the Board of Directors assesses that the proposed employee stock option plan is well-balanced and that it will be beneficial for the Company and its shareholders. (ii) Issue of warrants to IncentivesIn order to secure the Company’s commitments under Employee Stock Option Plan 2014 the Board of Directors proposes that the Annual General Meeting resolves on an issue of a maximum of 258,692 warrants, whereof a maximum of 45,192 warrants are intended to hedge the costs (mainly social security contributions or corresponding taxes) that may arise from the employee stock option plan, on principally the following terms: The warrants shall be issued free of charge and the right to subscription shall, with a deviation from the preferential right of the shareholders, be assigned to Incentives. Subscription of warrants shall take place at the latest on May 20, 2014, with the right for the Board of Directors to extend the subscription period. Each warrant shall entitle the holder to subscribe for one (1) new share in the Company at a subscription price equivalent to 110 per cent of the volume-weighted average price paid for a share in the Company on the NASDAQ OMX Stockholm during ten trading days following the 2014 Annual General Meeting, however never less than the share quotient value. Subscription for new shares in the Company with the support of the warrants shall take place no later than December 31, 2018. The new shares will entitle to dividend for the first time on the record date that occurs after the new shares has been registered at the Swedish Companies Registration Office (Sw: Bolagsverket) and after the shares have been recorded in the share register maintained by Euroclear Sweden AB. In the event that all warrants issued in respect of Employee Stock Option Plan 2014 are used to subscribe for new shares, the Company’s share capital will increase by SEK 25,869.20 from SEK 1,189,357.20 to SEK 1,215,226.40. This is equivalent to a dilution of approximately 2 per cent of the shares and votes in the Company. The reasons for deviating from the shareholders’ preferential rights are that the issue constitutes part of the implementation of Employee Stock Option Plan 2014. The Board of Directors assesses that a long-term personal ownership commitment among the employees will lead to an increased interest in the business and the result, and therefore improves the motivation of the employees. It is advantageous for the Company to be able to offer employees an opportunity to participate in the Company's development. The Board of Directors therefore assesses that the proposal, with regard to the terms, appears to be reasonable. (iii) Approval of transfer of warrants or shares in the Company to employees in the Company, etc.The Board of Directors proposes that the Annual General Meeting resolves to approve that Incentives is entitled to transfer warrants or shares in the Company to personnel in the Company and Moberg North America, who have received employee stock options under the Employee Stock Option Plan 2014, or otherwise dispose of the warrants, in order to secure the Company’s commitments and costs in connection with Employee Stock Option Plan 2014. Costs for Employee Stock Option Plan 2014The Board of Directors assesses that Employee Stock Option Plan 2014 will lead to costs partly in the form of accounting salary costs, partly in the form of social security contributions. These latter costs are hedged by the warrants issued with the purpose of covering these costs. Preparation of the proposal of Employee Stock Option Plan 2014The proposal regarding Employee Stock Option Plan 2014 has been prepared by the Company's Remuneration Committee and has been presented to the Board of Directors. Previous incentive programs in the CompanyFor a description of the Company’s other share-related incentive programs, reference is made to the Company’s 2013 annual report, and the Company’s website www.mobergpharma.com. In addition to the programs described, there are no other share-related incentive programs in the Company. Majority requirementThe Annual General Meeting´s resolution on the above items (i) – (iii) shall be adopted together as one resolution. A resolution in accordance with the Board of Director’s proposal requires the approval of shareholders representing at least nine tenths of the votes cast and the shares represented at the Meeting. Proposal for resolution regarding authorization for the Board of Directors to issue new shares (Item 16)The Board of Directors proposes that the Annual General Meeting authorize the Board of Directors to, within the scope of the articles of association, with or without deviation from the shareholders’ preferential right, on one or several occasions during the period until the next Annual General Meeting, resolve to increase the Company’s share capital by issuing new shares in the Company. The total number of shares issued in accordance with this authorization may be equivalent to a maximum of 20 per cent of the shares in the Company at the time of the 2014 Annual General Meeting. The issues shall be made with issue rates at market rate, and where applicable be subject to issue discount at market rate, and payment shall, apart from payment in cash, be made in kind or by set-off or otherwise with conditions. The purpose of the authorization and the reasons for any deviation from the shareholders’ preferential right is that the Company shall be able to carry out issues in order to finance the Company’s business, commercialization and development of the Company’s products and/or the acquisition of products, project portfolios, businesses, companies or parts of companies. The Board of Directors, CEO or such person as the Board of Directors authorize, shall be authorized to carry out amendments and clarifications of the Annual General Meeting’s decisions that are required in connection with the filing with the Companies Registration Office. A resolution in accordance with this proposal requires the approval of shareholders representing at least two thirds of the votes cast and the shares represented at the Meeting. Information at the Annual General MeetingShareholders may request that the Board of Directors and the Chief Executive Officer provide information regarding circumstances that may affect the assessment of an item on the agenda for the Annual General Meeting, and circumstances that can affect the assessment of the Company’s financial position. The Board of Directors and the Chief Executive Officer shall provide such information at the Annual General Meeting if they believe that it can be done without material harm to the Company. Shareholders wishing to submit questions in advance may send them to Moberg Pharma AB (publ), att. Anna Ljung, Gustavslundsvägen 42, 5 tr, 167 51 Bromma, Sweden, or by e-mail to anna.ljung@mobergpharma.se. DocumentsCopies of accounting documents and the audit report as well as forms of power of attorney will be available for shareholders at the Company and on the Company´s website www.moberpharma.com, as from Wednesday, April 16, 2014. Complete proposals as well as other documents according to the Swedish Companies Act will be available for shareholders at the Company and on the Company´s website as above, no later than Tuesday, April 22, 2014. All of these documents will also, without charge, be sent to shareholders who so request and state their address. _______________________________________ Stockholm in April 2014 Moberg Pharma AB (publ) The Board of Directors About this informationMoberg Pharma discloses the information provided herein pursuant to the Securities Markets Act and/or the Financial Instruments Trading Act. The information was submitted for publication at 8:30 am (CET) on April 14th, 2014.

Moberg Pharma acquires global rights to novel topical formulation for treatment of oral pain

Oracain has generated promising clinical data supporting safety and efficacy in several pilot studies – most importantly that the novel lozenge formulation provides significantly longer and better pain relief than currently available non-opioid treatment alternatives for patients with oral mucositis. Moberg Pharma plans to gain additional efficacy data through a phase II study during this year, to be followed by pivotal studies and registration. Under the terms of the agreement, Oracain is entitled to an upfront payment of 1 MSEK, additional 5 MSEK after successful phase II data have been generated and a share of future revenues after such revenues have exceeded Moberg’s accumulated development costs incurred prior to launch. The acquisition and cost for the phase II study are financed through available cash resources. Moberg Pharma plans to pursue several routes to generate near term revenues from the product, including through licensing marketing rights to partners in select territories after completion of phase II as well as through sales for compassionate use for individual patients. Since there is a pressing unmet medical need for pain relief in oral mucositis, the product can be supplied for such compassionate use in certain markets prior to regulatory approval. Moberg Pharma will also examine the possibility for orphan drug status, in the U.S. as well as in EU. Furthermore, Moberg Pharma has identified several additional potential indications for the product beyond oral mucositis, both in the acute and chronic setting, such as Sjögren’s Syndrome, Burning Mouth Syndrome, endoscopic procedures, oral intubations and long-term also OTC use. The company estimates the peak sales potential of the product to 50-100 m$ assuming successful commercialization in oral mucositis and at least one additional indication. “We are excited of the opportunity to create a best in class product for a pressing medical need and to make it available to patients within the next few years. Oral mucositis is a debilitating side effect of cancer therapy. Oracain’s clinical data is highly promising and indicates a potential to provide better and longer pain relief to patients. The acquisition is in line with our strategy of providing niche products that can create significant value based on proven molecules with limited development cost, risk and time to market”, said Peter Wolpert, CEO of Moberg Pharma AB. “Years of clinical practice in oral mucositis – and frustration of inadequate treatments for patients suffering of the severe and disabling mouth pain – were the driving forces behind our innovation. We are excited to partner with Moberg Pharma who has the capabilities to bring this important medical innovation to practical use and benefit for patients. The scientific team of Oracain is fully dedicated to support the continued development”, said Ove Andersen, Chairman of Oracain and inventor. About oral mucositis and the acquired technologyOral mucositis (“OM)” is a painful inflammation and ulceration of the mucous membranes lining the mouth. OM is a common and often debilitating complication of cancer treatment which affects 80% of patients with head and neck cancer receiving radiotherapy, almost all patients undergoing bone marrow transplantation, and a wide range of patients receiving chemotherapy. OM makes the patient less likely to comply with their cancer treatment, increases mortality and morbidity and contributes to rising health care costs. In the U.S., every year approximately 400 000 patients suffer from OM during cancer therapy.  The technology encompasses novel lozenge formulations of bupivacaine, a local anesthetic with a well-established long acting effect, currently available on the market for other indications as an injectable. The original innovation came out of work by clinicians at Hvidovre Hospital, Copenhagen, Denmark facilitated by XOventure GmbH and SEED Capital Denmark.   About this informationMoberg Pharma discloses this information pursuant to the Swedish Securities Markets Act and/or the Financial Instruments Trading Act. The information was submitted for publication at 08.30 am (CET) on April 14, 2014.

NOTICE OF ANNUAL GENERAL MEETING IN BONG AB (publ)

The shareholders of Bong AB (publ) are hereby invited to attend the Annual General Meeting to be held on Wednesday 21 May 2014 at 4.00 p.m. CET in Bong’s premises at Uddevägen 3 in Kristianstad. The registration desk will be open from 2.30 p.m. CET. A tour in the factory will be arranged at 3.00 p.m. – 3.45 p.m. CET. A. Right to attend Shareholders who wish to attend the Annual General Meeting (“AGM”) must –  be recorded in the share register kept by Euroclear Sweden AB made as of Thursday 15 May 2014, and –  notify the company of their intention to attend the AGM no later than Thursday 15 May 2014, by any of the following alternatives: · By post to the address:Bong AB (publ)Att: Katarina SjöströmHans Michelsensgatan 9SE-211 20 Malmö, Sweden · By telephone +46 40-17 60 41 · By telefax +46 40-17 60 39 · By e-mail to anmalan.arsstamma@bong.com · On-line at the company’s website www.bong.com (http://www.bong.com/en/corporate-governance/registration-annual-general-meeting-1.0.605.1) On giving notice of attendance, the shareholder shall state name, personal identity number or corporate identification number, address and telephone number, shareholding and the number of advisors that the shareholder wishes to bring to the General Meeting (maximum two advisors). Shareholders represented by proxy must issue a document authorising the proxy to act on the shareholder’s behalf. A proxy form is available on the company’s website www.bong.com (http://www.bong.com/en/corporate-governance/annual-general-meeting-2014) and will be provided to shareholders who contact the company and state their address. Representatives of a legal entity shall present a copy of the certificate of registration or similar document of authorisation showing the persons authorised to act on behalf of the company. The original of the proxy and the document of authorisation should be sent to the company together with the notice of attendance. In order to participate in the proceedings of the General Meeting, owners with nominee-registered shares must request their bank or broker to have their shares owner-registered with Euroclear Sweden AB. Such registration must be made as of Thursday 15 May 2014 and the banker or broker should therefore be notified in due time before said date. B. Agenda Proposal for Agenda 1. Opening of the Meeting. 2. Election of Chairman of the Meeting. 3. Preparation and approval of the voting list. 4. Approval of the agenda. 5. Election of one or two person(s) to approve the minutes. 6. Determination of compliance with the rules of convocation. 7. Report by the President and CEO. 8. Presentation ofa.      the Annual Report and the Auditor’s Report and the Consolidated Financial Statements and the Group Auditor’s Report,b.      the Board of Directors’ proposal for disposition of the company’s result, andc.      the statement by the auditor on the compliance with the guidelines for remuneration to management applicable since the last AGM, and 9. Resolution regardinga.      adoption of the Statement of Income and the Balance Sheet and the Consolidated Statement of Income and the Consolidated Balance Sheet,b.      appropriation of the company’s profit according to the adopted Balance Sheet, andc.      discharge from liability of the Board of Directors and the President and CEO. 10. Determination of the number of board members and deputies.11. Establishment of fees to the Board of Directors and the auditors.12. Election of the members of the Board of Directors and auditors.13. Election of members of the Nomination Committee.14. Guidelines for remuneration of senior executives.15. Closing of the Meeting. Proposals for Resolutions Appropriation of profit (9b)The Board of Directors has proposed that no dividend is to be distributed for the financial year 2013 and that the results of the company of totally SEK 739,522,181, including this year’s result of SEK -21,375,329 should be carried forward. Proposal of the Nomination Committee (item 2 and items 10-12)The Nomination Committee, consisting of Stéphane Hamelin (Holdham S.A.), Christian Paulsson (Paulsson Advisory AB) and Ulf Hedlundh (Svolder Aktiebolag), has made the following proposals: that   Mikael Ekdahl shall be elected Chairman of the AGM;that   the Board of Directors shall consist of six board members without any deputies;that   Stéphane Hamelin, Mikael Ekdahl, Anders Davidsson, Ulrika Eriksson and Eric Joan shall be re-elected as board members and that Christian Paulsson shall be elected as a new board member for the period up to and including the AGM 2015, whereby it was noted that Christian W. Jansson has declined re-election;that   re-election shall be made of Stéphane Hamelin as Chairman of the Board;that   fees to the board members shall be paid by totally SEK 900,000 (committee work excluded) to be distributed among the board members as follows: SEK 300,000 to the Chairman and SEK 150,000 to each of the other board members elected at General Meetings and not employed with the company, and fees for work in the Audit Committee shall be SEK 100,000 to the Chairman of the Audit Committee and SEK 50,000 to each of the members;that   the accounting company PricewaterhouseCoopers AB shall be elected auditor of the company for a one year period of mandate, consequently, up to and including the AGM 2015, whereby the accounting company has informed that the authorised public accountant Eric Salander will be appointed as auditor in charge, andthat   the auditor’s fees shall be paid as per agreement. Christian Paulsson (born 1975) has a Bachelor of Business Administration from European University Bruxelles and works in his own business as an active investor in smaller and medium-sized companies. Previous operational experiences includes inter alia deputy managing director and CEO of the business software company IBS AB and CEO of the securities brokerage company Lage Jonason AB. Prior to this, Christian Paulsson has extensive experience in Corporate Finance at inter alia Mangold Fondkommission, Alfred Berg/ABN Amro Fondkommission and Booz & Co. Christian Paulsson is a Board member of IBS AB (publ) and Apper Systems AB. Nomination Committee (item 13)Shareholders representing approximately 50 per cent of all shares and votes in the company have proposed that a Nomination Committee shall be appointed also for the AGM 2015 and: that   the Nomination Committee shall have three members;that   Stéphane Hamelin (Holdham S.A.), Christian Paulsson (Paulsson Advisory AB) and Ulf Hedlundh (Svolder Aktiebolag) shall be re‑elected as members of the Nomination Committee;that   Stéphane Hamelin shall be elected as Chairman of the Nomination Committee;that   if a shareholder represented by any of the members of the Nomination Committee should substantially reduce its shareholding in the company or in the event a member no longer is employed with such shareholder or for any other reason should leave the Nomination Committee before the AGM 2015, the Nomination Committee shall be entitled to appoint another representative of the major shareholders to replace such member; andthat   the tasks of the Nomination Committee shall be to prepare election of Chairman and other board members, election of auditor, election of Chairman of the AGM, fee issues and relating issues before the AGM 2015. Guidelines for remuneration of senior executives (item 14)The Board of Directors proposes that the AGM shall resolve for remuneration to the CEO and other senior executives as follows. By senior executives is meant officers of the management, at present consisting of the company’s CEO, Chief Financial Officer (CFO), Business Manager Nordic, Business Manager Central Europe, Business Manager United Kingdom and Business Manager France and Spain. Remuneration shall consist of fixed salary, variable remuneration, other benefits and pension. The aggregate remuneration shall be in accordance with market conditions and competitive in order to ensure that the Bong Group can attract and retain competent senior executives. In addition to the above variable remuneration, long term incentive programs may be resolved upon from time to time. The variable part of the salary shall have a pre-determined cap and may as a fundamental principle never exceed 60 per cent of the fixed annual salary. The variable part is based on earnings and cash flow as well as individual qualitative goals. The basic principle is that the variable remuneration is paid in accordance with the agreed-upon weighting between the interim goals if the interim goal has been achieved. The variable component is based on a vesting period of one year. The goals for senior executives are established by the Board of Directors. Pension benefits shall primarily be fee based, but can also for legal reasons be income based, although not at the Group Management level. Variable remuneration shall not qualify for pension. The Group Management is entitled to pensions under the ITP system or the equivalent. The retirement age is 65 years. In addition to the ITP plan, some members of Group Management are also entitled to an increased occupational pension premium so that the total equals 30 per cent of their fixed salary. The Group Management’s employment contracts include provisions governing remuneration and termination of employment. According to these agreements, employment can ordinarily cease on notice of termination by the employee within a period of notice of 4–12 months and on dismissal by the company within a period of notice of 6–18 months. On dismissal by the company, the period of notice and the period during which compensation is payable shall not together exceed 24 months. Remuneration to the CEO and other senior executives is prepared by the Board of Directors’ remuneration committee and resolved by the Board of Directors based on the remuneration committee’s proposal. These guidelines shall apply to those persons who are included in the Group Management during the period the guidelines are in force. The guidelines shall apply to the employment contracts entered into after the Annual General Meeting’s resolution, and to any changes in existing contracts. The Board of Directors shall have the right to deviate from the above guidelines if motivated by particular reasons on an individual basis. C. Available Documentation The accounting documents and the Auditor’s Report, the complete proposal of the Board of Directors for resolution according to item 14, as well as the statement by the auditor regarding whether the guidelines for remuneration to the management have been observed, are available to the shareholders at the company as from Wednesday 30 April 2014. Copies will also be sent to shareholders on request and be available at the General Meeting. The above documents and the Annual Report will as from said date also be available on the company’s website www.bong.com (http://www.bong.com/en/investors/annual-reports). D. Number of Shares and Votes in the Company At the issue of this notice, the total number of shares and votes in the company amounts to 156,659,604. E. Information at the AGM The Board of Directors and the CEO shall at the AGM, if any shareholder so requests and the Board of Directors believes that it can be done without significant harm to the company, provide information regarding circumstances that (i) may affect the assessment of an item on the agenda, (ii) circumstances that may affect the assessment of the company’s or its subsidiaries’ financial position and (iii) the company’s relation to other companies within the group. Kristianstad in April 2014 The Board of Directors BONG AB (publ) For further information please contact:Anders Davidsson, President and CEOPhone: +46 44 20 70 80 Håkan Gunnarsson, CFOPhone: +46 44 20 70 82 This information is of the kind that Bong AB (publ) are obliged to publish pursuant to the securities market act and/or the act on trade with financial instruments. The information was given for publication at 9.30 am on 14 April 2014. Bong is a leading provider of specialised packaging and envelope products in Europe, offering solutions for distribution and packaging of information, advertising materials and lightweight goods. Important growth areas in the Group are the Propac packaging concept and Russia. The Group has annual sales of approximately SEK 2.5 billion and about 2,000 employees in 15 countries. Bong has strong market positions in the majo­rity of key markets in Europe, and the Group sees interesting possibilities for continued expansion and development. Bong is a public limited company and its shares are listed on NASDAQ OMX Stockholm Small Cap.

Growth in Brazilian property market funded by World Cup feel good

It’s rare that football makes property markets flutter but that’s exactly what’s happening on the streets of Brazil. This year’s highly anticipated World Cup tournament is proving a boon for those invested in South American property. Buy to let investors are filling their boots before a ball has even been kicked. The Brazilian economy has grown rapidly and looks set to continue offering investors high emerging market returns at low risk. This has created a unique opportunity for those looking to get into the buy to let market. Rental yields of 8% to 11% per annum and an increase in the price of property of between 10% and 15% per annum are widely expected. Putting your money into South America If you’re looking to invest in South America Paul Smith, SWIM Worldwide Investment Management (http://www.swimworldwide.br.com/) feels it would be wise to speak to a local expert: “As a company, we don’t feel that we need to be spending a lot of effort, time and money to go global, when there is so much we can do to help our client’s in this particular region.” Notes to editors: * International Advisor Profile of SWIM Worldwide Investment Management Paul Scott http://www.international-adviser.com/profiles-and-analysis/profiles/living-in-the-fast-lane?page=1 **Brazil hailed as an exciting opportunity for buy to let investors http://www.propertywire.com/news/latin-america/brazil-buy-let-property-201403258933.html *** http://www.swimworldwide.com

Edgecam is the first CAD/CAM platform to integrate Sandvik Coromant Adveon™ Tool Library

Cutting tool and tooling systems supplier Sandvik Coromant has announced that CAD/CAM software specialist Edgecam is the first company to integrate the Sandvik Coromant Adveon™ Tool Library. Built into Edgecam’s 2014 R2 software release, Adveon will help customers to further improve machining productivity and security, and saves time during machine set-up. Edgecam is a market-leading CAD/CAM system for CNC part programming that supports a wide variety of milling, turning and mill-turn machining requirements including 3D milling and multi-axis operations. The platform combines ease-of-use with sophisticated toolpath generation and is used globally within a multitude of industries. The integration provides customers with a single source of data for multiple CNC systems. The library allows the rapid building of tooling databases and ensures automatic access to 3D CAD models for accurate simulation and visualisation. The engineer’s input is reduced, improving both consistency and quality of data. By offering a standardized methodology for cutting tool suppliers to deliver digital tool data to customers, Adveon simplifies and speeds CAD/CAM programming. Support for the ISO 13399 cutting tool data standard allows selection of tools from any supplier and assures the accuracy of the geometrical information. Customers can develop their own libraries, quickly build tool assemblies and see immediate results in 2D and 3D. Klas Forsström president of Sandvik Coromant comments: “Pressure to reduce time from design to production combined with the ever-increasing complexity of tools makes rapid access to accurate and current tool data more critical than ever. Companies can no longer afford to rely on manual data entry and operators need a single tool library that can manage tools from multiple manufacturers. Adveon has been designed from the ‘ground up’ to address these challenges.” Edgecam General Manager Raf Lobato says: “Integration of the Adveon tool library into the market-leading Edgecam CAD/CAM system will help customers boost productivity and security, especially in three- to five-axis manufacturing operations. Adveon will be included in all new Edgecam licences and will provide a single tool library for multiple applications.” Adveon will be free with Edgecam for 2014. Visitors to MACH 2014 will find demonstrations of the Edgecam platform with integrated Adveon tool library on the Edgecam stand (Hall 4: Stand 4426). Consultants will also be on hand to answer any questions regarding the latest version of the software. For further information please visit www.edgecam.com/adveon-edgecam  or www.sandvik.coromant.com/adveon. - End - About Sandvik Coromant Sandvik Coromant  (http://www.sandvik.coromant.com/) is a global leading supplier of cutting tools, tooling solutions and know-how to the metalworking industry. With extensive investments in research and development we create unique innovations and set new productivity standards together with our customers. These include the world's major automotive, aerospace and energy industries. Sandvik Coromant has 8000 employees and is represented in 130 countries. We are part of the business area Sandvik Machining Solutions within the global industrial group  Sandvik  (http://www.sandvik.com/). For more information visit the website at  www.sandvik.coromant.com . Contact Details: Nikki StokesPR & Advertising, EMEASandvik CoromantTel: +44 (0) 121 504 5422Email:  nikki.stokes@sandvik.comWebsite:  www.sandvik.coromant.com Birgit Schoeniger Senior Account ManagerPinnacle Marketing Communications, Ltd Tel: +44 (0) 208 429 6554Email:  b.schoeniger@pinnaclemarcom.comWebsite:  www.pinnacle-marketing.com Please consider the environment before printing this press release.                                       Ref: SAN756A

Securitas publishes Annual Report for 2013

The printed version of the Annual Report will be available as of today and will be distributed to those of Securitas’ shareholders who have ordered it from Securitas’ Shareholder Web service:  http://www.securitas.com/Order-and-subscribe/ Under the section Investor Relations, there is an overview of the Groups’ sales divided by business segment, further divided into the business segments’ sales per major country for 2013: http://www.securitas.com/Sales-per-country-overview There is a new interactive tool for annual and quarterly data: http://www.securitas.com/Annual-data and http://www.securitas.com/Quarterly-data The Annual General Meeting will be held at 4.00 p.m. CET on May 5, 2014, Hilton Hotell Slussen, Guldgränd 8 in Stockholm. This press release is also available at: www.securitas.com Information:Gisela Lindstrand, Senior Vice President Corporate Communications and Public Affairs, Securitas AB, phone +46 10 470 3011, mobile +46 70 287 8662, or email gisela.lindstrand@securitas.com Securitas is a global knowledge leader in security. From a broad range of services of specialized guarding, technology solutions and consulting and investigations, we customize offerings that are suited to the individual customer’s needs, in order to deliver the most effective security solutions. Everywhere from small stores to airports, our 300,000 employees are making a difference. Securitas AB discloses the information provided herein pursuant to the Securities Markets Act and/or the Financial Instruments Trading Act. The information was submitted for publication at 11.00 (CET) on April 14, 2014.

Leasedrive ranked 36th in The Sunday Times BDO Profit Track 100

The Leasedrive Group has been ranked 36th in the latest The Sunday Times BDO Profit Track 100, now in its 15th year, which ranks Britain’s 100 private companies with the fastest-growing profits over the last three years of available audited accounts. It was the second ranked company in the south east of England region. The UK’s largest independent privately-owned vehicle management group made its first appearance in the league table in 2011 and last year was placed 46th. Roddy Graham at the Leasedrive Group, said: “Our third appearance in The Sunday Times BDO Profit Track 100 recognises our rising profitable growth achieved in a highly competitive market sector. “This important recognition by The Sunday Times BDO Profit Track 100 independently endorses HgCapital’s recent majority investment and supports the European sector-focused private equity investor’s view on the management expertise and capability within our business. As always this accolade would not be possible without the support of all of our excellent people who constantly strive to deliver the highest quality bespoke vehicle management service. “For customers of our vehicle management division, the company car remains popular as both an essential business tool and as a perk to attract and retain the best people in the war for talent. Car salary sacrifice schemes are also highly popular as a tax efficient way of providing a new company car and eliminating the ‘grey’ fleet risk. Meanwhile, our rental management division is experiencing unprecedented growth.” The Sunday Times BDO Profit Track 100 citation* read: “This vehicle management firm was created in 2007 through the merger of Leasedrive and Velo. It leases 42,000 cars and vans to blue-chip companies across Britain such as Marks & Spencer, and advises on fuel efficiency and taxation. After buying rival Masterlease in 2011, managing director David Bird, 55, saw profits lift to £13.4m in 2012. It is integrating its operations with Zenith, a competitor also owned by HgCapital.” Earlier in the year, the Group won the 2014 Fleet News Award for ‘Customer Service’. *Reproduced by permission. Copyright The Sunday Times BDO Profit Track 100 Notes to Editors: Fast Track has published league tables of top-performing private companies with The Sunday Times for the past 17 years. Its invitation-only dinners provide a valuable opportunity for entrepreneurs to network and meet its sponsors. The company was founded and is run by Dr Hamish Stevenson, who also holds an associate fellowship at Green Templeton College, Oxford University. League table criteria Companies had to be registered in the UK and be independent, unquoted and ultimate holding companies. Companies are ranked according to the compound annual growth in their profits over three years, based on their latest figures (either 2009 to 2012, or 2010 to 2013). The research therefore carries the caveat that their performance may have changed since. Profits are defined as operating profit with directors’ remuneration added back. The research was carried out by Fast Track between 1 November 2013 and 14 February 2014. The majority of companies were interviewed by telephone and/or visited by the Fast Track research team. The sponsors do not endorse, guarantee or recommend investment in any of the companies. About BDO Accountancy and business advisory firm, BDO LLP, is the UK member firm of the BDO International network. In April 2013, BDO LLP merged with PKF (UK) LLP to form a new force in the mid-market, employing 3,500 people across the UK. BDO LLP has a clear ambition to be the firm known in the market for exceptional service delivered by empowered people. The 2013 Mid Market Monitor analysis shows that BDO is the market leader for client satisfaction for the second year running. www.bdo.co.uk About Lloyds Bank Commercial Banking Lloyds Bank Commercial Banking delivers corporate banking and financial services to businesses. We are proud to continue our association with the Profit Track 100, demonstrating our commitment to supporting the growth of UK businesses. www.lloydsbankcommercial.com About UBS Wealth Management UBS Wealth Management provides a complete range of financial services in the UK. Our team has a unique blend of private banking, corporate finance and financial planning expertise which enables us to devise innovative solutions that address the big issues for UK entrepreneurs. www.ubs.com/uk

Bernarda Pera wins Aegon GB Pro-Series Gloucester

For Saturday’s singles final of the women’s $10,000 event, Oxstalls Sports Park welcomed The Right Worshipful Mayor of Gloucester Chris Chatterton and the Sheriff and Deputy Mayor of Gloucester Said Hansdot alongside other dignitaries and a large crowd of spectators. A number of Oxstalls Be Inpsired girls’ competitions had been organised throughout the week to promote girls’ tennis and compliment the women’s international ITF Pro Circuit tournament. The girls have had the opportunity to meet the professional players, and Bernarda Pera even presented the prizes for the mini orange and green competition on Friday. One lucky girl from Saturday’s mini red competition was selected to do the coin toss for the women’s final. The singles finalists, Bernarda Pera (USA) & Klaartje Liebens (BEL), both 19 years old, are no strangers to ITF Pro Circuit finals, having amassed 17 appearances between them during their relatively young professional careers. The Belgian made the first break through in the second game to take a 2-0 lead, however, it was short lived as Pera fought back to level the score. Settling into the final each player then managed to hold serve, wowing the crowd with their array of shots. Pera took a strong hold on the match when breaking Liebens again in the seventh game and dropped only three points in next three games to establish a one set lead. After an early exchange of breaks in the second set, the young American powered her way from the back of the court, using her leftie serve to great effect. With the momentum firmly back with her, Pera reeled off four consecutive games to seal victory with a clenched fist, winning 63 61. The title at Gloucester is Pera’s first of 2014, adding to the three titles she won in 2013, and helping her move toward her career high ranking of 354 that she achieved in October last year. After the match Pera said “It always feels good to win of course, especially as it was a tough draw this week. I didn’t start so well, I dropped my serve in the second game, but I came back and I am happy. When asked about her best memory of the week, Pera said “I think it would be the final as there were a lot of people watching, there was great support.”

Pricer is revolutionizing the shopping experience in Carrefour

Pricer, the world leader in providing Electronic Shelf Label solutions, has announced that Carrefour, the world’s second largest retailer, will use Pricer’s latest retail technology for a fully-connected store that significantly improves the customer experience. Carrefour Villeneuve la Garenne is the first store worldwide that allows customers to benefit from Pricer’s integrated solution using indoor navigation, mobile shopping and SmartTAG graphic labels. “Carrefour came to us 6 months ago searching for ideas to modernize the shopping experience in their stores,” says Arnaud Lecat, VP Store Solutions at Pricer, “Pricer delivered a solution enabling Carrefour to interact with their customers through their smartphones and the ESLs.” The mobile App created for Carrefour called "C-où", which is available on Android and iOS, allows customers to create shopping lists, search products, get promotions, find recipe ideas. The solution also includes geolocalisation – once inside the store, it helps you find any product, and optimises your shopping route through indoor navigation. The store has been equipped throughout with over 55 000 Pricer NFC-enabled ESLs. Not only do these bring all the benefits of ESLs – including centralized price automation – but customers can even ‘like’ a product with their phone and the label will display the total number of ‘likes’. “We are proud to play a role in this prestigious project,” concluded Lecat. “For Carrefour, customer service is paramount – it is a retailer that understands that innovative new technologies can enrich this experience, and therefore boost customer loyalty.” Press contact:Milla NurmikkoMulberry Marketing Communications/+44 (0) 207 928 7676/ mnurmikko@mulberrymc.com Niclas QvistPricer/+33 (0)1 61 08 40 20/ niclas.qvist@pricer.com   In its capacity as issuer, Pricer AB is releasing the information in this press release in accordance with the Swedish Securities Exchange Act (2007:528). The information was distributed to the media for publication at 14:45 hrs CET on Monday, April 14th, 2014. Pricer provides the retail industry’s leading electronic display and Electronic Shelf Label (ESL) platform, solutions, and services for intelligently communicating, managing, and optimizing price and product information on the retail floor. The platform is based on a two-way communication protocol to ensure a complete traceability and effective management of resources. The Pricer system significantly improves consumer benefit and store productivity by simplifying work in the store. Pricer, founded in 1991 in Uppsala, Sweden, offers the most complete and scalable ESL solution. Pricer has installations in over 50 countries with the largest ESL world market share. Customers include many of the world’s top retailers and some of the foremost retail chains in Europe, Japan and the USA. Pricer, in co-operation with qualified partners, offers a totally integrated solution together with supplementary products, applications and services. Pricer AB (publ.) is quoted on the Nordic Small Cap list of OMX. For further information, please visit www.pricer.com

Announcing a Second Crowdfunding Campaign for Nix Sensor, a Portable Color Detection Device

HAMILTON, Ontario – After a strikingly successful Kickstarter crowdfunding campaign that enabled the first shipment of the award winning color sensor, Nix Sensor announces a second crowdfunding campaign through Indiegogo. The new project ends on April 20, 2014, and will allow the company to manufacture a second batch of the Nix Sensor. The product is available at a discounted price through the campaign. All funds raised through the Nix Sensor campaign will pay for the manufacturing of the device. The company expects a fast turnaround since they have already fulfilled an order once before. Backers can expect their new color-matching device delivered to them in May of this year. Early bird supporters of the Indiegogo project will receive 50% off the retail price of the device. Only 100 slots are available for the early bird special. Other supporters receive the color sensor at 30% off. The patent pending color sensor is compatible with iPhone, Android, PC, and Mac. It stores accurate color properties, which can be matched to real life color pigments. Colors of images or objects can be scanned and saved on the device with a swatch name and description. The swatch can then be viewed in any color model including RGB, CMYK, HSL, HSV, XYZ, HTML, and Lab. Next, the swatch can be converted to multiple mediums including wall paint, oil paint, makeup, watercolor, hobby paints, wood stain, automotive paint and more. Even crayon color can be selected for serious coloring book artists. Then, the user can select a particular brand of that medium. For instance, various brands of wall paint can be selected such as Behr, Sherwin-Williams, Ralph Lauren, etc. Once the color, medium type, and brand are selected, the user can search for a nearby store that sells the color product. Nix Sensor is a perfect small device for interior designers, fine artists, makeup artists, architects, and anyone who deals with creating color services. The useful tool can replace bulky paint deck systems of various paint manufacturers, therefore saving money and space. To become a supporter, visit http://www.indiegogo.com/projects/the-nix-color-sensor-batch-2. About Nix Sensor Ltd.: Nix Sensor was developed by a team of three entrepreneurial engineers in an effort to create an accurate color sensor that works regardless of ambient lighting and human error. The company’s team is made up of Matthew Sheridan, Andy Li, and James Strack and is located in Hamilton, Ontario, Canada. To view more about the new device and the company, visit http://www.nixsensor.com/. 

Proposal to the 2014 AGM from the Nomination Committee of Oriflame Cosmetics S.A.

The Nomination Committee today announces its proposal to the Annual General Meeting on 19 May 2014. The proposal will also be presented in the notice to attend the Meeting. – We regret that as a consequence of the new EU directives, Oriflame can no longer benefit from Marie Ehrling's competence and experience, which have been important to the company's performance during the seven years she served as a director. Meanwhile, we are pleased to welcome Anna Malmhake with the experience she brings in fast moving consumer goods, marketing and international operations. The proposal of Alexander af Jochnick as chairman is natural when the af Jochnick family is, and aim to continue to be, the company's majority owner. Alexander knows Oriflame well from over fifteen years within the company, having first worked in the operations and then served on the Board, says Chairman of the Nomination Committee Per Hesselmark. Election of Board members and the Chairman of the BoardThe Nomination Committee proposes re-election until the end of the next Annual General Meeting of Alexander af Jochnick, Robert af Jochnick, Jonas af Jochnick, Anders Dahlvig, Lilian Fossum Biner, Helle Kruse-Nielsen, Christian Salamon and Magnus Brännström and also that Anna Malmhake be elected as new Board member for the same period. The Nomination Committee proposes Alexander af Jochnick to be elected Chairman of the Board. Short facts on the proposed changes of the BoardMarie Ehrling has, following new EU regulations, limited the number of Board representations and therefore declined re-election to the Board. Robert af Jochnick, one of the company’s founders, has declined re-election as the Chairman of the Board but remains a member of the Board. Alexander af Jochnick has been a member of the Board since 2007. He was an employee of the company during 1999-2007. He is member of the Remuneration Committee and of the Audit Committee. Alexander af Jochnick was born 1971 and holds a MSc in Business Administration from Stockholm School of Economics and started his career at Boston Consulting Group. He is Chairman of Oriflame Foundation, and board member of CL Intressenter AB, Credus Management AB, Postkodstiftelsen and NC Holding AB. Alexander af Jochnick is the founder and board member of Serious Nature. Alexander af Jochnick owns 418,884 shares in Oriflame. Anna Malmhake was born 1966. She holds a BSc from University of Stockholm. Anna Malmhake is Chairman and CEO of Irish Distillers Pernod Ricard since 2011. Her previous career includes executive positions with Absolut Vodka, Coca-Cola Sverige, Temo AB, Motorola and Procter & Gamble. Anna Malmhake owns no shares in Oriflame. Independence according to Swedish Code for Corporate GovernanceAll of the proposed Board members are according to the Nomination Committee to be considered as independent in relation to the company's major shareholders except for Alexander af Jochnick, Robert af Jochnick and Jonas af Jochnick. Magnus Brännström is the CEO of Oriflame. For additional information, please contact:Per Hesselmark, Chairman Chairman of the Nomination Committee: +46 8 622 36 00 Appendix: Photo of Alexander af Jochnick and Anna Malmhake.

Notice of the 2014 Annual General Meeting and Extraordinary General Meeting of Oriflame Cosmetics

The Annual General Meeting ("AGM") of Oriflame Cosmetics S.A. (the "Company") will be held at the offices of the Company at 24 Avenue Emile Reuter, L-2420 Luxembourg on 19 May 2014 at 11 a.m. An Extraordinary General Meeting ("EGM") of the Company will be held at the same place immediately after the closing of the AGM. Selection of proposals for the AGM and EGM Proposal for the Board of Directors The Nomination Committee’s proposal for Board members entails the re-election of all members except for Marie Ehrling who has declined re-election. In addition, Anna Malmhake is proposed as a new Board member. The Board’s current Chairman, Robert af Jochnick, has declined re-election as Chairman and it is proposed that Alexander af Jochnick take over the role as Chairman of the Board. Continued alignment of the legal structure – relocation of the Group’s domicile As announced in April 2013, Oriflame is reviewing its legal structure. Today, the Board proposes that shareholders, at an Extraordinary General Meeting on 19 May 2014, take decisions to enable taking the next step in the previously communicated alignment of the legal structure to Group operations in order to enable further efficiencies, which includes a forthcoming relocation of the Group’s domicile from Luxembourg to Switzerland. Further information about the proposal will be published in a separate press release. Proposal for dividend – adjustment The Board has adjusted its proposal for dividend and proposes that a cash dividend of up to a total of EUR 1.00 per share be paid, and that payment will be made on a quarterly basis with the first payment of EUR 0.25 per share after the Annual General Meeting, and that the Board be given a mandate to decide the timing and size of the subsequent quarterly payments. The amended proposal supports the Company’s planned alignment of its legal structure and change of domicile, and will enable one or more payments from a legal entity other than Oriflame Cosmetics S.A. In addition, the proposal will ensure the realisation of full utilisation of the benefits of quarterly payments, aimed at optimising cash flow and the balance sheet. The complete list of business: see the enclosed PDF document.            For additional information, please contact:Johanna Palm, IR Director +46 765 422 672 Oriflame grundades i Sverige 1967. I dag är Oriflame ett internationellt, direktförsäljande kosmetikföretag med försäljning i över 60 länder. Oriflame har ett brett produktutbud av svenska, innovativa skönhetsprodukter inspirerade av naturen. Dessa produkter marknadsförs av omkring 3 miljoner oberoende Oriflame-konsulenter som tillsammans svarar för en årsomsättning på cirka 1,5 miljarder euro. Respekt för medmänniskor och natur är en viktig del av företagskulturen och återspeglas i bolagets riktlinjer för socialt arbete och miljöarbetet. Oriflame stödjer ett flertal välgörenhetsorganisationer världen över och är medgrundare av World Childhood Foundation. Oriflame är en koncern med säte i Luxemburg, och med globala kontor i Luxemburg och Schweiz. Oriflame är noterat på Nasdaq OMX, Stockholm.

JMC Steel Group Announces Plant Modernization Project for Wheatland Tube Location

Chicago, IL (April 14, 2014) – Wheatland Tube, a JMC Steel Group operating company, has launched a revitalization program for its Council Avenue location in Wheatland, Pennsylvania. The company is adding new equipment, realigning the manufacturing footprint and automating many processes in the facility.  Over the next two years, the thirty five million dollar ($35,000,000.00) investment will create a safer, cleaner workplace, eliminate production bottlenecks, reduce work in process inventory levels, enhance production efficiencies, improve product quality and improve customer service. At a recent meeting with Wheatland Tube employees, Barry Zekelman, Chairman and Chief Executive Officer of JMC Steel Group commented, “We know that the products this facility produces are both unique to the industry and second to none in their quality. For years we have discussed the need to update the equipment and production environment of this facility in order to continue to successfully compete at a global level. We are proud to take this step with the employees of Council Avenue and the Wheatland Tube community. We believe in the products that this facility produces and the people that produce them.  The result will be a revitalized and modernized facility which will be poised to aggressively grow the standard pipe market and compete long into the future.” Mark Magno, President of Wheatland Tube, stated “This project represents an incredible investment in Wheatland Tube by JMC Steel Group and the Zekelman family for our customers and employees.  For years, this facility has been negatively affected by high levels of  unfairly traded imports.  The new equipment and revitalized facility will allow us to provide our customers with unmatched quality and service.” According to Wheatland Tube General Manager Tim Feeney, “We are extremely excited by this announcement.  This investment solidifies the future of Wheatland Tube as the world’s premier continuous weld pipe manufacturer.”  

NOTIFICATION OF THE ANNUAL GENERAL MEETING

Kongsberg, April 10 201 The shareholders are hereby notified of the ordinary Annual General Meeting of Kongsberg Automotive Holding ASA on 7th May 2014 at 10 AM. Venue: Thon Conference Vika Atrium Munkedamsveien 45 0121 Oslo. The following items are on the agenda: 1.         Opening of the Annual General Meeting by the Chairman of the Board 2.       Presentation of the list of shareholders and proxies in attendance 3.         Election of a chairman of the meeting and a co-signer for the minutes 4.       Approval of the notification and agenda 5.      Adoption of the consolidated and parent company financial statements, including the allocation of the profit for the year Reference is made to the annual report available at the company’s web pages (www.kongsbergautomotive.com) and the Board of Directors’ proposed resolutions (attached). 6               The Company’s statement of remuneration to leading employees. The statement is attached, an advisory vote will be held. 7.      Election of directors of the Board and stipulation of remunerations to the Board of Directors The Nomination Committee’s recommendation is attached. 8        Election of members of the Nomination Committee, and stipulation of the remuneration to the Nomination Committee, Audit Committee and Compensation committee. The Nomination Committee’s recommendation is attached. 9       Stipulation of the Auditor’s fee.           The Board of Directors’ recommendation is attached 10      Amendment to the Articles of association           Proposal to amend the company name to ”Kongsberg Automotive ASA” 11.     Share option program           The Board of Directors’ recommendation is attached. 12.     Authorization for the purchase of own shares The Board of Directors’ recommendation is attached. 13.     Authorization to increase the company's share capital The Board of Directors’ recommendation is attached. Shareholders who are unable to attend the Annual General Meeting personally are entitled to be represented by a proxy. This will require a written and dated power of attorney. The enclosed proxy slip may be used. A company certificate should be enclosed with the proxy in the event that the principal is a corporate entity. Shareholders who wish to attend the Annual General Meeting themselves, or by proxy are required to register as soon as possible and no later than 2nd May 1200 CET to Nordea Bank Norge ASA, Issuer Services, Postbox 1166 Sentrum, 0107 Oslo, Fax (+47) 22 48 63 49 or issuerservices.No@nordea.com. Please use the enclosed attendance slip/proxy form. The Company’s annual report and annual accounts are available at the Company’s web pages www.kongsbergautomotive.com. Other documents that will be presented at the general meeting and proposals for resolutions are accessible at the same web site. The annual report will also be sent by mail upon request to the company, phone +47 32 77 05 00. The company has issued 406,768,131 shares each carrying one vote. All shares enjoy equal rights. At the date of this notification, the company owned 6,572,268 treasury shares for which voting rights may not be exercised. The shareholders may require board directors and the CEO to furnish in the general meeting available information about matters that may affect the consideration of a) the approval of the annual accounts and the annual report, b) any matters submitted to the shareholders for decision and c) the company’s financial position, and the business of other companies in which the company participates and any matter which the general meeting is to deal with unless the information required cannot be given without disproportionately harming the company. Representatives of the management and the board of directors will be present also after the general meeting to answer any other question that the present shareholders may have Kongsberg, 10th April 2014 For the Board of Directors of Kongsberg Automotive Holding ASA Ulla-Britt Fräjdin-Hellqvist Chairman of the Board See attached document for complete invitation and attendance slip

IFPA, ILDS and IPC form partnership to develop Global Psoriasis Atlas

(April 15, Stockholm)   While studies over the recent years have contributed to an improved understanding of psoriasis, there are still significant gaps in knowledge related to the epidemiology of this serious, chronic disease and trends in incidence over time. The World Health Organization (WHO), reported in 2013 that the worldwide prevalence of psoriasis is around 2%, but that studies in developed countries have declared prevalence rates of more than twice the global estimate at an average of 4.6%[1] (http://file:///O:/IFPA/2014/Psoriasis%20Atlas/IFPA,%20ILDS%20and%20IPC%20form%20partnership%20to%20develop%20Global%20Psoriasis%20Atlas%20-%20press%20release%20April%2015.docx#_ftn1). The project’s initial task therefore will be to establish a credible and reliable database recording the prevalence of psoriasis worldwide and by country. “By gathering data on the prevalence of psoriasis from as many countries as possible we will be able to form a clear picture of the burden of psoriasis worldwide and in so doing inform better decision making on the use of resources,” says Professor Wolfram Sterry, president of the ILDS. While gathering detailed information on prevalence, the initiative will undertake to build a framework for improved collection of data on the burden of psoriasis. In the long-term, the aim is to look at incidence over time and the burden associated with comorbidities as well as the economic impact of psoriasis. “The atlas project is about driving constant improvement in the understanding of psoriasis and encouraging the ongoing collection of data and research,” according to Professor Christopher Griffiths, president of the IPC. The development of a Global Psoriasis Atlas is a long-term project that seeks both to drive continuous improvement in the understanding of psoriasis and uncover how it affects both the individual and society at large. Due to lack of evidence, among other factors, recognition of psoriasis as a serious, noncommunicable, chronic disease that is widespread and represents a significant public health challenge is poor – at both the local and global level. Lars Ettarp, president of IFPA explains that, “building an evidence base that all stakeholders can use to advocate for improved treatment, access to care and recognition of psoriasis is a priority. Only once we truly understand the burden will we be able to command the recognition that people living with psoriasis deserve.” About the Global Psoriasis Atlas Project The objectives of this joint project are to: · Build an evidence base that stakeholders can use to advocate for improved treatment, access to care and recognition of psoriasis as a priority of public healthcare policy. · Unite all stakeholders on one mutually beneficial agenda that works towards improving the lives of people with psoriasis and psoriatic arthritis. · Encourage collection of data and research into psoriasis that could ultimately lead to better use of resources, as well as improvements in treatment and care. · Enable benchmarking within and between countries by providing all stakeholders with local and regional evidence that is consistent and comparable. About the partners The International Federation of Psoriasis Associations (IFPA) The International Federation of Psoriasis Associations (IFPA) is a nonprofit organisation made up of psoriasis associations from around the world. IFPA unites psoriasis associations so that their global campaign for improved medical care, greater public understanding and increased research will improve the lives of people who live with psoriasis and psoriatic arthritis.  Through cost effective, successful and high quality programmes such as World Psoriasis Day and the World Psoriasis & Psoriatic Arthritis Conferences, IFPA brings together psoriasis associations, healthcare professionals and the healthcare industry to actively pursue the vision of a world without human suffering from psoriasis. To learn more about IFPA please visit www.ifpa-pso.org. The International League of Dermatological Societies (ILDS) The International League of Dermatological Societies (ILDS) is a non-governmental organisation in official relations with the World Health Organization. It was formed to: · Stimulate the cooperation of societies of dermatology and societies interested in all fields of cutaneous medicine and biology throughout the world · Encourage the worldwide advancement of dermatological education, care and sciences · Promote personal and professional relations among the dermatologists of the world · Represent dermatology in commissions and international health organisations · Organise a World Congress of Dermatology every four (4) years To learn more about ILDS please visit http://web.ilds.org. The International Psoriasis Council (IPC) Founded in 2004, The International Psoriasis Council (IPC) is a dermatology led, voluntary, global nonprofit organisation dedicated to innovation across the full spectrum of psoriasis through research, education and patient care.  The mission of the IPC is to empower our network of global key opinion leaders to advance the knowledge of psoriasis and its associated comorbidities, thereby enhancing the care of patients worldwide. To learn more about IPC visit www.psoriasiscouncil.org. ---------------------------------------------------------------------- [1] (http://file:///O:/IFPA/2014/Psoriasis%20Atlas/IFPA,%20ILDS%20and%20IPC%20form%20partnership%20to%20develop%20Global%20Psoriasis%20Atlas%20-%20press%20release%20April%2015.docx#_ftnref1) World Health Organisation. Psoriasis report by the Secretariat. Executive board, 133 session, provisional agenda item 6.2. 5 April 2013. ----------------------------------------------------------------------

Changes in management

The following changes have been made in the Group’s Russian business: - Eduard Gaidar appointed Russia Managing Director. Mr Gaidar was previously Head of Logistics for Russia. - Torbjorn Karlsson appointed Russia COO. Mr Karlsson was previously Head of Agronomy Russia. Eduard Gaidar (age 46) has worked with Agrokultura the since 2010. Prior to this he worked as a project manager in a food and dairy business. He also worked for PepsiCo and Gallina Blanca companies involved in starting up their new branch offices in Russia. He holds a university degree in crisis management from Moscow State University of Economics, Statistics and Informatics. He will focus on running the non-farming aspects of the business in Russia. Mr Gaidar lives and works in Voronezh, Russia. Torbjorn Karlsson (age 38) joined Agrokultura’s Russian business in February 2010 following two years as a production director at Black Earth Farming. Mr Karlsson has MSc in Agronomy from Swedish University of Agricultural Sciences. Prior to moving to Russia, Mr Karlsson worked from 2002 to 2008 as a crop consultant in Farmers’ Cooperative Lantmännen in Sweden. Mr Karlsson is responsible for Russian farming related operations and lives and works in Voronezh, Russia. Following the resignation of the Deputy Managing Director in December 2013 and following the promotion of Kristian Shaw to Group CFO, both the posts of Deputy Managing Director and Deputy CFO have remained and will remain unfilled. In addition the former roles of the new Russian Managing Director and COO will not be filled. Stephen Pickup, Managing Director commented: “I am delighted to welcome Eduard and Torbjorn into their new roles. Both have considerable experience with the company and their appointment will streamline the Russian management team whilst clarifying reporting structures. The ambitious targets we have set for cost cutting require all staff to take on responsibility and I am pleased there is enthusiasm within the business to do this. I would like to thank Jens Peter Aabyen and Igor Suvorov respectively former Russia Managing Director and Russia COO for their contributions over the past years.”Stockholm, 15 April 2014Stephen Pickup, Group Managing Director, tel. +44 782 529 4352Kristian Shaw, Group CFO, tel. +44 782 529 4356

SKF First-quarter report 2014

Tom Johnstone, President and CEO:“Sales developed well in the first quarter compared to the low first quarter last year and were relatively unchanged compared to the fourth quarter. We continued to have a negative mix in our sales with a stronger development of our automotive business and our industrial OEM sales in Asia. The possible pre-buy ahead of the price increase in the aftermarket in Europe and North America was not as anticipated.   During the quarter we received a number of awards and continued to strengthen SKF by gaining new business, launching a number of new products and making good progress with our cost reduction programme.   Kaydon is developing well and had a first good quarter. The integration is proceeding according to plan with a strong focus on both sales and cost synergies.   Agreement was reached in the quarter with the European Commission regarding theirinvestigation and is within the amount taken as a provision in the fourth quarter last year.This will be paid in June and will impact cash flow in the second quarter.      Going forward we expect demand to develop positively both sequentially and comparedto the second quarter last year. Manufacturing will be higher year on year and slightlyhigher compared to the first quarter.” Key figures Q1 2014 Q1 2013Net sales, SEKm 16,734 15,152Operating profit, SEKm 2,024 1,480Operating margin, % 12.1 9.8Operating margin excl. one-time costs, % 11.4 11.4Profit before taxes, SEKm 1,787 1,237Net profit, SEKm 1,275 818Basic earnings per share, SEK 2.72 1.74 Operating profit for Q1 includes the net positive effect of one-time items totalling around SEK 120 million. As a result of the settlement with the European Commission a reversal of SEK 150 million was made related to the provision taken in Q4 2013. The quarter also contained one-time items of around SEK 30 million related to restructuring as well as a negative revaluation effect due to the devaluation of the Argentine peso. Net sales change y-o-y, Volume Price/ Structure Currency Totalin SEK,attributable to: mix effectQ1 2014 6.2% -0.4% 4.7% -0.1% 10.4% Sales in the first quarter in local currencies and excluding structure increased by 4.4% in Europe, by 2.9% in North America, by 4.1% in Latin America, by 10.6% in Asia and by 21.4% in Middle East and Africa.Manufacturing in the first quarter was higher compared to last year. Outlook for the second quarter of 2014 Demand compared to the second quarter 2013The demand for SKF’s products and services is expected to be slightly higher for the Group, North America and Asia. It is expected to be relatively unchanged for Europe and slightly lower for Latin America. For Strategic Industries and Automotive it is expected to be slightly higher and for Regional Sales and Service relatively unchanged. Demand compared to the first quarter 2014The demand for SKF’s products and services is expected to be slightly higher for the Group, for North America and Asia. It is expected to be relatively unchanged for Latin America. For Strategic Industries and Automotive it is expected to be slightly higher and for Regional Sales and Service relatively unchanged. ManufacturingManufacturing is expected to be higher year over year and slightly higher compared to the first quarter. Gothenburg, 15 April 2014 Aktiebolaget SKF       (publ) A teleconference will be held on 15 April at 09.00 CEST, 08.00 (UK):SE: +46 (0)8 505 564 74UK: +44 (0)203 364 5374 You will find all information regarding SKF First-quarter results 2014on the IR website.investors.skf.com/quarterlyreporting AB SKF is required to disclose the information provided herein pursuant to the Securities Markets Act and/or the Financial Instruments Trading Act. The information was submitted for publication at around 08.00 on 15 April 2014.

NMG: NOTICE of Extraordinary General Shareholders’ Meeting in Nickel Mountain Group AB (publ) on May 8, 2014

Notice is hereby given of an Extraordinary General Meeting (EGM) with the shareholders of Nickel Mountain Group AB (publ), 556227-8043, on Thursday, May 8, 2014 beginning at 10.00 in the office of the Company at the address Kungsgatan 44, 7th floor in Stockholm. Right to participate at the Extra General Meeting Shareholders who wish to participate in the EGM must, -      firstly be recorded in the share register maintained by Euroclear Sweden AB on Friday, May 2, 2014 (see also under the headline Nominee-registered shares below), and -      secondly notify the Company at the address Kungsgatan 44, 7thfloor, 111 35 STOCKHOLM about their intention to attend the EGM not later than 16.00 on Friday, May 2, 2014 by phone +46 8 402 28 00, by fax +46 8 402 28 01 or by mail to torbjorn.ranta@nickelmountain.se . When notifying the company, please state your name, personal identity/registration number, address, shareholding and details about any assistants (not more than two). Nominee-registered shares Shareholders whose shares are nominee-registered must also request a temporary entry in the register of shareholders kept by Euroclear Sweden AB in order to be entitled to participate at the EGM. Shareholders must notify the nominee about this well in advance of Friday May 2, 2014, which is the day when such entry must have been executed in order to be considered in the excerpt of the share register, made by Euroclear Sweden AB. Shareholders registered in the Norwegian Verdipapirsentralen (VPS) must request temporary entry as shareholders in the register of shareholders kept by Euroclear Sweden AB in order to be entitled to participate at the EGM. In connection thereto, shareholders must notify DNB Bank ASA about this at the addressVerdipapirservice, Postboks 1600 Sentrum, 0021 Oslo or by fax: +47 24 05 02 56, or by email: vote@dnb.no no later than 12.00 noon CET on Monday, April 28, 2014, in order for DNB Bank to be able to ensure that entry is made in the register of shareholders kept by Euroclear Sweden AB by Friday the 2nd of May, 2014, which is the day when such entry must have been executed. Following the EGM, DNB Bank will arrange for shareholders to be re-registered in the Norwegian Verdipapirsentralen. Proxy etc. The rights of shareholders during the EGM may be exercised by an authorized representative (proxy). Any proxies must be presented in original. Proxies in original can be sent to the company at the following address: Nickel Mountain Group AB, Kungsgatan 44, 7 trp, 111 35 Stockholm, Sweden. A proxy form will be available at the company’s website www.nickelmountain.se .  (http://www.ige.se/)Representatives of legal entities must present registration documents in original or certified copy of the same or equivalent proof of authorization. Proposed agenda 1. Opening of the EGM. 2. Election of Chairman of the EGM. 3. Drafting and approval of voting list. 4. Approval of agenda. 5. Appointment of persons to keep and approve the minutes. 6. Determination whether the EGM has been duly convened. 7. Approval of the Board’s proposal to conduct a set-off issue 8. Approval of the Board’s proposal to decide on a divided 1:1 of all the shares in the subsidiary African Diamond AB 9. Other items10. Closing of the EGM The Board of directors’ proposal for decisions §7 The Board’s proposal for a set-off issue The Board of Directors propose that the EGM decides on an increase of the Company’s share capital by SEK 737,309.50 by issuing 1,474,619 new shares with a subscription price of SEK 3.80 per share. The other conditions are proposed to be the following: · The new shares are only supposed to be subscribed to as described below: Subscriber           Number of shares     Loan amount to be set-off (SEK)Altro Invest AB      1.179.580                    4.482.404Renud Invest AS      114.997                      436.988,60Svein Breivik          153.132                      581.901,60     Ole Weiss               26.910                     102.258                      1.474.619             5.603.552,20 · Subscription of and payment for the new ordinary shares must take place latest on May 30, 2014. The Board of Directors of the Company shall be authorized, in case need arises, to decide on a prolongation of the subscription- and payment period. · Payment shall be executed via set-off of claims in an amount corresponding to SEK 5,603,552.20. The set-off shall be considered executed when the subscription list has been signed. · The new shares shall be entitled to receiving dividends, if such ones get declared, for the first time on the record date that occurs after the date when the set-off issue      has been registered by the Swedish Companies Registrar (“Bolagsverket”). · After the registration of the set-off issue amounting to 1,474,619 new shares by the Swedish Companies Registrar, the total share capital of the Company will amount to SEK 11,351,170 and the new number of shares outstanding will be 22,702,340. · The parties entitled to subscribe for new shares according to above, and who are either directly or indirectly via representatives, Board members of the Company, have  committed to set off claims on the company as described above. The set off issue is conducted as a means of strengthening the balance sheet of the Company by reducing debt. The subscription price, SEK 3.80 per share, has been agreed between the subscribers and the Company, and represents a premium of some 50% to the current market price on the stock exchange (as per closing price on April 10, 2014). As a consequence of the subscribers being either directly or indirectly Board members of the Company, it is necessary according to the Chapter 16 provisions of the Swedish Companies Act (also called “Lex Leo”), that the decision at the Extraordinary General Meeting is taken by a quorum representing at least 90% of the votes present and of the shares actively voting at the EGM. §8 The Board’s proposal to give a dividend 1:1 of all the shares in wholly-owned subsidiary African Diamond AB The Board of Directors propose that the Extraordinary General Meeting decide on distributing as a dividend all the shares of wholly-owned subsidiary African Diamond AB pro rata to the shareholders of Nickel Mountain Group AB. In this context, it is proposed that 1 existing share of Nickel Mountain Group AB gives the right to receive 1 share of African Diamond AB. The total dividend, according to the book value of African Diamond AB, corresponds to SEK 556,558.50 as per March 31, 2014, which corresponds to SEK 0.025 per Nickel Mountain Group share after the above set-off issue. The Board of Directors shall be authorized to decide on a record date for the dividend, which however shall occur after the registration of the set-off issue above according to §7 by the Swedish Companies Registrar, but before the 2014 Annual General Meeting. Miscellaneous Required documentation covering §§ 7 and 8 above, as well as other information required according to the Swedish Companies Act will, at the latest two weeks before the EGM, be available in the office of the Company and on the Company’s website, www.nickelmountain.se ,  (http://www.ige.se/)and will be sent free of charge by mail to shareholders who so request and state their address. The shareholders are reminded of their right to request information in accordance with Chapter 7 Section 32 of the Swedish Companies Act. The number of shares outstanding in the Company at the time of this EGM-notice is 21,227,721. *** Stockholm, April 15, 2014 Nickel Mountain Group AB (publ) The Board of Directors

Update of the Mineral reserve for Dannemora Mineral

Mineral reserve Dannemora Mineral’s mineral reserve as of 31 December 2013 shows a probable mineral reserve of 29.1 million tonnes with an average grade of 34.2 percent Fe. This is a decline in tonnage compared with the previous estimate in December 2012, which was 34.0 million tonnes and 34.5 percent Fe. Here are the main reasons for the reduction in the reserve: ·2.6 million tonnes were mined in 2013. ·A temporary cut-off level of 30 percent Fe is being used from 2013 up to the end of 2015. This means that areas in the mine with grades of between 20 and 30 percent Fe have been left and will continue to be left for the time being. After 2015 a cut-off level of 20 percent Fe will be reintroduced. There is therefore a total reduction in the probable mineral reserve of 4.9 million tonnes and a reduction in the Fe grade of 0.3 percent Fe. Probable mineral reserve Mt Fe %2012 34.0 34.52013 29.1 34.2 Mineral resources The estimated mineral resources for Dannemora Mineral as of 31 December 2013 amounted to 28.1 million tonnes with an average Fe grade of 39.2 percent (measured and indicated mineral resources). The new estimate shows measured mineral resources of 17.5 million tonnes with an average grade of 39.5 percent Fe, indicated mineral resources of 10.6 million tonnes with an average grade of 38.6 percent Fe, and inferred mineral resources of 4.9 million tonnes with an average grade of 37.6 percent Fe. The inferred mineral resources have increased even though only limited drilling took place in the new areas of the mine. The main reason for this increase is because some of the resources that were previously classified as measured have been transferred to inferred mineral resources. In 2014 the company plans to increase its drilling in order to investigate new magnetite mineralisations that have been discovered and to extend existing ore bodies. Measured Indicated Inferred mineral resources mineral mineral resources resources Mt Fe % Mt Fe % Mt Fe %2012 19.8 38.7 13.6 37.9 1.9 41.12013 17.5 39.5 10.6 38.6 4.9 37.6 Only measured and indicated mineral resources are used to estimate the mineral reserve. The mineral resources are reported including the mineral reserve. The mineral resources and mineral reserve for 2013 were estimated by Dannemora Magnetit’s geology and planning staff in collaboration with Thomas Lindholm, Geovista AB, Luleå. The mineral resource estimate was produced by Gunnar Rauseus (Geologist), Peter Svensson (Geologist) and Thomas Lindholm (Mining Engineer). The mineral reserve was then estimated by Daniel Eklund (Mining Planner), Peter Svensson (Geologist), Mats Larsson (Planning Manager) and Thomas Lindholm (Mining Engineer). All work was carried out under the supervision of the company’s independent qualified person Thomas Lindholm, GeoVista AB, Luleå. Thomas Lindholm is a Fellow of AusIMM (Australasian Institute of Mining and Metallurgy) and has the required knowledge and experience in reporting this type of deposit.

Sanofi launches Probi Digestis® in Korea

Probi has signed a distribution and supply agreement with Sanofi. Following this the Consumer Healthcare divison of Sanofi Korea is making a major launch of Probi´s gut health product, Probi Digestis®starting in April 2014. Probi has already delivered products and received substantial orders for the coming quarters. Sanofi is a leading Healthcare company with more than 100.000 employees worldwide and plays an important role in the global probiotic consumer market. Sanofi’s Consumer Healthcare division in Korea offers diverse vitamins, minerals, and health supplements under the well-established Cenovis brand. Sanofi Korea is one of the major players in dietary supplements in the mass retail channel in Korea. “Probiotics is the next major growth category in Korea and the launch of Probi Digestis®will be our focus for the Cenovis brand in 2014 and 2015. In Probi Digestis® we found a high quality probiotic product with good clinical documentation and we plan to extend the Probi range further, so it will play an important role in the Cenovis probiotic strategy going forward” says DongWoo Shin, head of Consumer Healthcare Sanofi Korea. Probi Digestis® will be launched in all channels Sanofi Korea is currently operating in, mass retail, department stores, drugstore/pharmacy, internet and TV home shopping. The product will be sold with Probi Digestis® predominantly displayed on front of the pack and Sanofi will make substantial consumer marketing investment during the launch. “Probi is looking forward to further strengthen our presence in the fast growing Asian markets together with Sanofi Korea and the strong Cenovis brand” says Peter Nählstedt, CEO of Probi. Peter Nählstedt adds, “Sanofi is a strong global player and has potential of quickly becoming one of our largest customers.” The South Korean market for probiotic supplements is estimated to have a value of USD 54 million. The annual growth rate over the past five years has been on avarage 15 percent however the growth rate is expected to be even higher in the coming years. The increasing health awareness and disposable income are positive factors driving the market growth in Korea. Probi Digestis® is based on Lactobacillus plantarum 299v (DSM 9843), which targets bloating, gas formation and pain, common symptoms that are sometimes mild or temporary but often more severe and diagnosed as IBS – Irritable Bowel Syndrome. The information is such that Probi AB must disclose in accordance with the Swedish Securities Market Act and/or the Financial Instruments Trading Act. FOR FURTHER INFORMATION, CONTACT:Peter Nählstedt, CEO, Probi, tel +46 46 286 89 23 or mobile +46 723 86 99 83, e-mail: peter.nahlstedt@probi.seNiklas Bjärum, VP Marketing & Sales, Probi, tel +46 46 286 89 67 or mobile +46 705 38 88 64, e-mail: niklas.bjarum@probi.se ABOUT PROBIProbi AB is a Swedish publicly traded biotechnology company that develops effective and well-documented probiotics. Through its research, Probi has created a strong product portfolio in the gastrointestinal health and immune system areas. The products are available to consumers in more than 30 countries worldwide.  The customers are leading food, health-product and pharmaceutical companies in the Functional Food and Consumer Healthcare segments. Probi had sales of MSEK 102 in 2013. The Probi share is listed on NASDAQ OMX Stockholm, Small-cap. Probi has approximately 3,500 shareholders. Read more on www.probi.se. ABOUT SANOFISanofi, an integrated global healthcare leader, discovers, develops and distributes therapeutic solutions focused on patients’needs.  Sanofi has core strengths in the field of healthcare with seven growth platforms: diabetes solutions, human vaccines, innovative drugs, consumer healthcare, emerging markets, animal health and the new Genzyme. Sanofi is listed in Paris (EURONEXT: SAN) and in New York (NYSE:SNY). In Korea, Sanofi has four legal entities in the fields of pharmaceuticals and consumer healthcare (sanofi-aventis Korea), vaccines (Sanofi Pasteur), rare disease (Genzyme Korea), and animal health (Merial Korea).

Assar Gabrielsson Award for research that may provide better treatment of glandular cancer

Cancer is a condition caused by various types of damage to the genetic material (DNA). One such change is the emergence of fusion oncogenes, which can occur when damage is repaired incorrectly so that the genetic material from two chromosomes joins together. Increased knowledge about the links between fusion oncogenes and cancer is therefore important in order to understand how cancer occurs, which in turn can promote new and better treatment methods. “Marta Persson has in particular studied the molecular and clinical significance of the existence of fusion oncogenes. She has obtained results that may be significant in the treatment of the most common form of cancer in the salivary gland,” says Eva Forssell-Aronsson, Executive Member of the Assar Gabrielsson Foundation. In her doctoral thesis at University of Gothenburg, Marta Persson successfully linked together clinical information about patients with laboratory-based analyses. She currently holds a post-doctoral position in Professor Göran Stenman’s research team at the Sahlgrenska Cancer Center and is working on a project that is a direct continuation of her thesis speciality – adenoid cystic carcinoma (a malignant salivary gland tumour). Assar Gabrielsson was one of the founders of Volvo, together with Gustaf Larson. In accordance with Assar Gabrielsson’s wishes, a foundation to provide funding for clinical research into cancer diseases was created in 1962. The foundation aims particularly at furthering cancer research together with Gothenburg University. The Assar Gabrielsson Award also offers a research grant of SEK 100,000. AB Volvo has contributed to the fund’s capital and the fund is now able to contribute about five million kronor annually in research grants to young cancer researchers. April 15, 2014 Journalists, who would like further information, please contact: Professor Eva Forssell-Aronsson, Executive Member of the Assar Gabrielsson Foundation, mobile +46 703 72 26 26. Read more about the Assar Gabrielsson Foundation at www.agfond.se

TeliaSonera’s Interim Report January-March 2014

Wednesday April 23, 2014 Press and Analyst ConferenceTime: 10:30 (CET)Place: TeliaSonera’s Head Office, Stureplan 8, Stockholm Mr Johan Dennelind, President and Chief Executive Officer of TeliaSonera and Mr Christian Luiga, Senior Vice President and Chief Financial Officer of TeliaSonera will present the Interim report January-March, 2014. Press identification card or similar is required to attend. The press and analyst conference will be held in English and will be webcasted at www.teliasonera.com (http://www.teliasonera.com/en/). Telephone conference in connection to the press and analyst conferenceYou can also listen to the conference live over the phone and attend the Q&A session via a conference call. To ensure that you are connected to the conference call, please dial in a few minutes before the start of the press and analyst conference to register your attendance. Dial-in numbers:+44 (0) 1452 588 613, 0800 694 57 28 Access code:29653940 Please note that there might be a time lag of up to 30 seconds between the webcast and the conference call if you are simultaneously watching and calling in to the press and analyst conference. You can also listen to the conference call afterwards until April 29, 2014. Replay number:+44 (0) 1452 55 00 00Access code:29653940   For more information, please contact the TeliaSonera press office +46 771 77 58 30, press@teliasonera.com, visit our Newsroom (http://www.teliasonera.com/en/newsroom/) or follow us on Twitter @TLSN_Media (https://twitter.com/TLSN_Media). TeliaSonera provides network access and telecommunication services in the Nordic and Baltic countries, the emerging markets of Eurasia, including Russia and Turkey, and in Spain. TeliaSonera helps people and companies communicate in an easy, efficient and environmentally friendly way. Our ambition is to be number one or two in all our markets, providing the best customer experience, high quality networks and cost efficient operations. TeliaSonera is also a leading wholesale provider who owns and operate one of the world’s most extensive fiber backbones. In 2013, net sales amounted to SEK 101.7 billion, EBITDA to SEK 35.6 billion and earnings per share to SEK 3.46. The TeliaSonera share is listed on NASDAQ OMX Stockholm and NASDAQ OMX Helsinki. Read more at www.teliasonera.com.     

Scania to deliver 200 refuse trucks to Italy

The trucks will be supplied to Amsa S.p.A., a provider of street cleaning and waste management services, which operates in both centralMilanand surrounding municipalities. The company issued the tender with the aim of strengthening the fleet of vehicles used by its urban refuse collection service. Scania and its bodybuilding partner Farid Industrie worked together on the tender application to produce a framework agreement for rear-loader trucks. The agreement will mean delivery of up to 100 diesel trucks and up to 100 compressed natural gas (CNG) trucks over a period of 24 months from the signing of the contract. The vehicles will be 3-axle Scania P-series trucks and will be powered by a 9-litre 250 or 280 hp engine. “This order is extremely important as it represents further advancement of our relationship with both AMSA and Farid Industrie,” says Franco Fenoglio, Managing Director at Italscania S.p.A. “We will supply the client with a high-quality product, tailor-made for this specific application. The Euro 6 engine range, which includes diesel and gas versions, is the perfect choice for operators with strict environmental sustainability demands.” The vehicles are covered by service contracts through Scania’s workshop network. The close collaboration with Farid Industrie has allowed Scania to significantly increase its market share in the public and special-purpose segments in Italy over the past 18 months. For more information, please contact Hans-Åke Danielsson, Press Manager, tel +46 8 553 856 62.

Allison equipped line painting truck offers improved performance, increased safety and reduced driver workload.

Millbrook, UK – When local authorities and line painting contractors look to replace their vehicles involved in line painting duties, there are a range of options to consider from the choice of truck itself, to transmission and interior. Specialist engineering firm Rexmar Engineering designs and builds bespoke vehicle bodies that maximise operator safety and driver operation, with Allison fully automatic transmissions central to each customer build. The company supplies a number of councils and contractors up and down the UK. As with all road vehicles, the marketplace for road marking trucks has seen a move towards cleaner, safer and more economical vehicles. In November 2014, new type approval legislation will place further emphasis on improved emissions and increased safety features. Rexmar’s response is a fully-equipped DAF LF55 220 line painting truck. The DAF LF55 features a 6.7-litre PACCAR GR engine producing 165 kW / 224 hp partnered with an Allison 3000 SeriesTM transmission. The LF55 has a gross vehicle mass ranging from 12 to 19 tonnes and gross payloads from 10.7 to 14 tonnes. The 3000 Series transmission, designed for medium-duty commercial vehicles and engineered to adapt and operate efficiently in a variety of applications, includes close or wide ratio gearing and a maximum rating of 336 kW (450 hp).   Safety and ease of operation are essential for road marking, with two 300 litre pots containing paint material operating at very high temperatures that must be accurately applied onto the road surface. Fully automatic transmissions make this job easier. Not only are these vehicles involved in a persistent stop-start duty cycle but, once in motion, marking vehicles must maintain specific speeds to ensure consistent application of the material. This is easier to achieve without the requirement to operate a clutch and manually change gears during operation. Martin Prosser, Rexmar managing director comments, “With ever stringent health and safety legal requirements and testing relating to type approval, we specify vehicles that are relevant for our customers for the whole of their life cycle. At the build stage Allison transmissions can be easily integrated. For example, the PTO pump can be packaged with the gearbox ‘straight out of the box’, without any re-working required. As an overall package, the ease of use and reduced down time that our customers experience make Allison the first choice in ensuring the overall proposition is future-proofed.” Operation of these vehicles is often at night when the roads are free of busy traffic or can be closed completely. Noise must be kept to a minimum, particularly when operating in residential areas. The Allison transmission’s helical planetary gear sets not only deliver uninterrupted gear changes and ensure maximum engine power and torque flow to the driving wheels for efficient acceleration, they greatly reduce noise. In some road marking vehicles, the addition of a smaller, secondary engine is required to power the pump; but with an Allison fully automatic transmission, a hydraulic pump is coupled to the transmission doing away completely with the so called ‘donkey engine.’ This also dramatically reduces noise. There are further benefits in reduced maintenance and down time for vehicles equipped with an Allison transmission. The patented torque converter offers not only excellent vehicle startability, but also eliminates costly clutch replacements. The complete drivetrain is protected against vibrations and wear and tear, improving component life cycles and saving on maintenance costs. This most advanced road marking truck boasts other impressive safety features: there has been a switch from using a gas fired burner to heat the paint material prior to marking, to a diesel fired unit, mounted at 90° to the pot, with a deflector that sends heat directly to where it is needed. Not only is this more economical, with a more even distribution of heat achieved throughout the mixing pots, the operation is far safer. LED lights are fitted so that other road users can easily identify the vehicle. The firm has already delivered several of these line painting trucks in 2013 and 2014. # About Allison Transmission Allison Transmission (NYSE: ALSN) is the world’s largest manufacturer of fully automatic transmissions for medium- and heavy-duty commercial vehicles, and is a leader in hybrid-propulsion systems for city buses. Allison transmissions are used in a variety of applications including refuse, construction, fire, distribution, bus, motorhomes, defense and energy. Founded in 1915, the company is headquartered in Indianapolis, Indiana, USA and employs approximately 2,700 people worldwide. With a market presence in more than 80 countries, Allison has regional headquarters in the Netherlands, China and Brazil with manufacturing facilities in the U.S., Hungary and India. Allison also has approximately 1,400 independent distributor and dealer locations worldwide. For more information, visit allisontransmission.com. # Press Enquiries Claire Dumbreck                                                           Miranda Jansen Propel Technology                                                        Allison Transmission Europe claire@propel-technology.com                 miranda.jansen@allisontransmission.com +44 (0)1295 770602                                                      +31 78-6422 174 Unit 4, Manor Farm Offices,                                       Baanhoek 118 Fenny Compton, Warks, UK                                        Sliedrecht, The Netherlands

Owners made final commitment to Fennovoima

April 15, 2014 Fennovoima’s owners Voimaosakeyhtiö SF and RAOS Voima Oy have today on April 15th made the binding decision to construct and finance Fennovoima’s nuclear power plant in Pyhäjoki. Fennovoima supports Finland’s competitiveness and the operations of its owner companies. The project increases Finland’s self-sufficiency in electricity generation and strengthens the security of supply. According to the agreed schedule, the power plant will generate electricity for its owners at cost price starting from 2024. The power plant will employ directly thousands of people during construction period and generates durable demand for various services in Finland and especially in Northern Ostrobothnia. The Fennovoima general meeting that was held today has nominated a new board. The Chairman of the Board is Juhani Pitkäkoski, Senior Vice President of M&A of Caverion Corporation and the Vice Chairman is Anastasia Zoteeva, Deputy Director General for Business Development of Rusatom Overseas. The Members of the Board are Aimo Eloholma, former Board Chairman of Megafon (Russia); Esa Lager, former CFO of Outokumpu Oyj; Juha Mäkitalo, Attorney-at-Law; Stefan Storholm, CEO of Katternö Group and Djurica Tankosic, President of Global Nuclear of Worley Parsons. The Deputy Members of the Board are Antti Koskelainen, Energy Director of Outokumpu Oyj and Jussi Lehto, CEO of Keravan Energia. The former Chairman of the Board of Fennovoima Pekka Ottavainen will continue in his position as the CEO of Voimaosakeyhtiö SF, the majority owner of Fennovoima. RAOS Voima Oy, the subsidiary of JSC Rusatom Overseas and a part of the State Atomic Energy Corporation Rosatom, became Fennovoima's owner in March 2014 with a share of 34 %. Fennovoima’s majority owner Voimaosakeyhtiö SF aims at keeping its ownership in Fennovoima in the current 66 %. The Ministry of Employment and the Economy of Finland is preparing a proposal for Fennovoima’s application to supplement the Decision-in-Principle. If the Government approves the supplement, the application will proceed to Parliamentary ratification. For more information: CEO of Voimaosakeyhtiö SF Pekka Ottavainen, tel. +358 20 757 9247 Chairman of the Board of Fennovoima Juhani Pitkäkoski through Manager, PR and International Communications Tiina Tigerstedt, tel. +358 20 757 9211 Deputy Director General for Business Development of Rusatom Overseas Anastasia Zoteeva, through Director, Social Responsibilities Irina Kibina, +7 495 730 0873 ext. 5269

Heart of the South West LEP welcomes RGF funding

The Heart of the South West (HotSW) Local Enterprise Partnership (LEP) has welcomed the announcement that four organisations in the area have been awarded government funding to help boost growth across the area.  Two Plymouth based businesses - Becton Dickinson U.K. Limited and Fine Tubes Limited – along with Torquay based Gooch and Housego and economic delivery agency, North Devon+, have been awarded a share of the government’s £3.2 billion Regional Growth Fund (RGF), designed to help companies in England grow.Run by the Department for Business, Innovation and Skills, the RGF was established to support projects and programmes that raise private sector investment to create economic growth and sustainable employment. Six rounds of RGF funding are being released between 2011 – 2015 and the current round (five) is worth a total of £300 million.Chris Garcia, Chief Executive of the HotSW LEP said: “This is excellent news as it will boost growth and increase employment in our area.  Some of our other businesses have received support through previous funding rounds and we believe it is making a real difference.    “There is abundant potential, vision and ambition for business growth across the area – we’ve got a wealth of companies across a wide variety of sectors who want to expand given the right conditions.  This new programme is set to directly help businesses to unlock that potential, helping them to expand and create sustainable and long-term jobs.”

Good market uptake for Simeprevir during the first quarter 2014

Stockholm, Sweden — Medivir AB (OMX: MVIR) announces a good market uptake and strong sales development for simeprevir during the first quarter 2014. In light of this, Johnson & Johnson and Medivir are now disclosing the simeprevir sales in conjunction with Johnson & Johnson’s first quarter report 2014. The global first quarter sales (Net sales) of simeprevir amounted to 354 MUSD, of which 291 MUSD were sales in the USA. Medivir’s royalties based on these sales amounted to 162 MSEK (18 MEUR) for the first quarter. “We are looking forward with confidence to a continued good sales development for simeprevir and the increasing royalty revenue according to our license agreement“, said Maris Hartmanis, Medivir’s CEO. Medivir will publish its first quarter report on May 8, 2014. Medivir will host a short telephone conference today. Conference call Date: 15 April 2014Time: 14.45 (CET) Phone numbers for participants from: England +44 (0)20 707 532 17US +1 866 565 2905Sweden +46 (0)8 619 75 30Code 946208# For more information please contact: Rein Piir, EVP Corporate Affairs & IR, mobile: +46 708 537 292 Medivir is required under the Securities Markets Act to make the information in this press release public. The information was submitted for publication at 13.55 CET on 15 April 2014.   About Simeprevir Simeprevir is an NS3/4A protease inhibitor jointly developed by Janssen R&D Ireland and Medivir AB and indicated for the treatment chronic hepatitis C infection in combination with pegylated interferon and ribavirin in HCV genotype 1 and 4 infected patients with compensated liver disease, including cirrhosis. Janssen is responsible for the global clinical development of simeprevir and has exclusive, worldwide marketing rights, except in the Nordic countries. Medivir AB retains marketing rights for simeprevir in these countries under the marketing authorization held by Janssen-Cilag International NV. Simeprevir was approved for the treatment of chronic hepatitis C infection as part of an antiviral treatment regimen in combination with pegylated interferon and ribavirin in genotype 1 infected adults with compensated liver disease, including cirrhosis in September 2013 in Japan, in November 2013 in Canada and the U.S. and in March 2014 in Russia. A Marketing Authorisation Application was submitted to the European Medicines Agency (EMA) in April 2013 by Janssen-Cilag International NV seeking approval of simeprevir for the treatment of genotype 1 or genotype 4 chronic hepatitis C and the Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion, recommending Marketing Authorisation in the European Union for the use of simeprevir in combination with other medicinal products for the treatment of chronic HCV. This application is under review by the EMA. About Medivir Medivir is an emerging research-based pharmaceutical company focused on infectious diseases. Medivir has world class expertise in polymerase and protease drug targets and drug development which has resulted in a strong infectious disease R&D portfolio. The Company’s key pipeline asset is simeprevir, a novel protease inhibitor for the treatment of hepatitis C that is being developed in collaboration with Janssen R&D Ireland. The company is also working with research and development in other areas, such as bone disorders and neuropathic pain. Medivir has also a broad product portfolio with prescription pharmaceuticals in the Nordics.

Aesculap Academy Offers Course for Neuro and Orthopedic Spine Surgeons on Pathologies and Surgical Techniques of the Cervical Spine

Aesculap Academy (http://www.aesculapimplantsystems.com/spineacademy) is pleased to offer a surgical skills course, Pathologies and Surgical Techniques of the Cervical Spine (http://www.aesculapimplantsystems.com/spineacademy), for Neuro and Orthopedic surgeons in the United States and Canada that specialize in spine surgery. The course presents innovative approaches for posterior and anterior cervical fixation as well as advanced techniques in occipitocervical fixation through didactic sessions and a cadaveric workshop. The Pathologies and Surgical Techniques of the Cervical Spine (http://www.aesculapimplantsystems.com/spineacademy) course will take place on June 7, 2014 in Henderson, Nevada. With the launch of the Caspar Cervical Plating System in 1982, Aesculap set a milestone in the treatment of diseases of the cervical spine. That tradition of innovation continues today and during this course the latest technologies in cervical plating and fusion will be presented: · Quintex® Anterior Cervical Plating System (http://www.aesculapimplantsystems.com/quintex), a versatile plating system for ACDF procedures that allows surgeons to customize the biomechanical construct performance at each level based on individual patient needs. · PL-AGE®* Anterior Cervical Fusion System (http://www.aesculapimplantsystems.com/plage), is a one-piece titanium implant that offers a translational design and textured surface for surgical flexibility and efficiency as well as an environment that promotes fusion. · CeSpace™XP Cervical Interbody System (http://www.aesculapimplantsystems.com/cespacexp), is an optimum fusion of the osteoconductive Plasmapore®XP coating and PEEK-Optima®** core for enhanced implant stability, artifact-free imaging, and an ideal scaffold for ACDF procedures. · SecureSpan™ Laminoplasty Fixation System (http://www.aesculapimplantsystems.com/securespan), is an easy-to-use, stable system for precise fixation when treating diseases of the spine such as cervical stenosis and myelopathy. · S4®C (http://www.aesculapimplantsystems.com/default.aspx?pageid=395) is a system for posterior column fixation, possessing small implant volume, overall biomechanical strength and easy access instruments to help achieve a fast and efficient surgical procedure with optimal patient outcome. Backed by a panel of leading spine surgeons, the course enables participants to analyze and treat complex cervical pathologies and apply these new technologies through a combination of didactic classroom lectures featuring applicable case studies as well as a cadaveric lab for hands-on exposure to implants and instrumentation. The Pathologies and Surgical Techniques of the Cervical Spine (http://www.aesculapimplantsystems.com/spineacademy) course will be held on June 7, 2014 in Henderson, NV. For more information on attending the course visit http://www.aesculapimplantsystems.com/spineacademy or call 1-800-258-1946 x5223. *PL-AGE is a registered trademark of Rhausler, Inc.**PEEK-Optima is registered trademark of Invibio Biomaterial Solutions.

Arise successfully issues a five year green bond of SEK 1.1 billion

Arise AB has today successfully issued a five year senior secured green bond of SEK 1.1 billion with a floating rate of 3 months STIBOR + 3 percent p.a. The bond matures in April 2019. Arise AB will apply for a listing of the bonds on NASDAQ OMX Stockholm. In connection with the transaction the company’s debt is reduced with about SEK 90 million and negative interest rate hedges of another ca SEK 70 million are terminated. Together with a slightly improved amortization profile of the bond it means that the company’s cash flow will improve by just over SEK 30 million per year, on average, during the next five years. This is the first senior secured bond issue in Sweden in the wind power sector. The security of the bond consists of a number of wind farms in the southern part of Sweden, all with good production and operating history. The bond replaces the current bank debt financing of the secured wind farms and allows the company to diversify its financing on favorable terms in the credit market. “The interest for Arise and the bond has been strong. The fact that the bond also has an environmental quality stamp has been important for many investors”, comments Arise AB’s Head of Corporate Finance Linus Hägg. Regarding green bond and DNV GL’s opinion Arise AB has today issued a senior secured “green bond” to re-finance 10 of its wind energy assets. DNV GL has given an opinion stating that the bond meets the criteria for the Green Bond Principles. The Green Bond Principles were established in January 2014 by a number of international banks to, inter alia, standardize the green bond market. By this opinion the green integrity of the bond is verified. DNB Markets has acted as financial advisor to Arise and Sole Bookrunner for the issue, while Setterwalls has acted as legal advisor to Arise and Mannheimer Swartling has acted as legal advisor to the Sole Bookrunner. Halmstad, 15 April 2014 ARISE AB (publ) For further information, please contact Linus Hägg, Head of Corporate Finance, Arise AB, +46 702 448 916 The information contained herein constitutes information which Arise AB is legally required to publish under the Swedish Securities Market Act (2007:528) and/or the Swedish Financial Instruments Trading Act (1991:980). The information was released for publication at 15.15 p.m. on 15 April 2014.

Euro 6 – the challenge was to win

“Euro 6 has been a challenge for the entire industry,” says Joel Granath, Head of Product Management for Scania trucks. “Many predicted increased fuel consumption with increased complexity. Now the jury is in – at the end of last year, for example, a Scania Streamline G 410 set two undisputed records for 40-tonne trailer combina­tions when German and French trade press journalist’s tested it on well-established and de­manding test tracks. According to the media, no equivalent rig, regardless of emission class, had previously passed the demanding route* north of Munich in just over 24 litres/100 km.” Former concerns about Euro 6 have proved unfounded. Despite this, it seems as if both Scania and other manufacturers had a strong influx of customers during the autumn of 2013, many customers wanting to lock in a Euro 5 truck order before the new year.“Our customers are living with tough competition and I understand that some chose security over the unknown. But whoever chooses Scania also chooses proven tech­nology with Euro 6,” emphasizes Joel Granath. “Three years have passed since Scania delivered the first-generation Euro 6 engines. Today, there is indisputable evidence in the form of operating data from our customers that Scania made the right choices in development.”                            Joel Granath declines to go into the extent of the resources Scania has invested in its Euro-6 programs but emphasizes instead the achievements in terms of, for example, the breadth of the engine range using alternative fuels: “Scania has presently eleven diesel engines, two gas engines and five engines for 100 percent biodiesel in the Euro-6 engine range. We can offer solutions for all applications and needs. I am especially proud of the low consumption figures we reach with Scania Streamline. Our 13-litre, inline six with 410 horsepower and SCR only, was developed with European long-haulage operators in mind and has exceeded all expec­tations. It is a typical example of Scania's main focus, to reduce our customers total operating costs.” * Link to the German trade magazine “Trucker”: http://www.trucker.de/scania-g-410-im-supertest-1312407.html Scania’s present Euro 6 engine range: +------+------+------+--------+--------------+--------------+--------------+|DC09 |DC13 |DC16 |DC09 Gas|DC09 Biodiesel|DC13 Biodiesel|DC16 Biodiesel|+------+------+------+--------+--------------+--------------+--------------+|250 hk|370 hk|520 hk|280 hk |320 hk |450 hk |580 hk |+------+------+------+--------+--------------+--------------+--------------+|280 hk|410 hk|580 hk|340 hk |360 hk |490 hk | |+------+------+------+--------+--------------+--------------+--------------+|320 hk|450 hk|730 hk| | | | |+------+------+------+--------+--------------+--------------+--------------+|360 hk|490 hk| | | |+------+------+------+--------+--------------+--------------+--------------+

Notice of Nexam’s Annual General Meeting 2014

NotificationA complete notice follows below and is also available at Nexam’s website www.nexam.se (http://www.nexam.se/agm2014). Complete notice will also be inserted in Post- och Inrikes Tidningar on 16 April 2014. The fact that notice to attend a shareholders’ meeting has been published will be announced on the same day in the Swedish newspaper Svenska Dagbladet. The notice is also available at Nexam’s head office and is sent free of charge upon shareholder's request. Notice to attendShareholders wishing to attend the AGM must, first, be listed in the share register kept by Euroclear Sweden AB on Thursday May 8, 2014 and secondly, on Thursday May 8, 2014, they must have informed Nexam of their attendance and number of assistances, if any, by email to till Ann-Gerd Salmonson, ann-gerd.salmonson@nexam.se. Such notification can also be given by telephone +46 76-108 18 00, or mail to Nexam  Chemical Holding AB (publ), Bolagsstämma, Medicon Village, Scheelevägen 2, 223 81 Lund, Sweden. Notification ought to include the shareholder’s name, address, telephone number, personal or corporate identity number, registered shareholding and information on number of assistances, if any. Notification and particulars of any proxy and assistances will be registered with Nexam to provide the basis for the voting list. Shareholders represented by proxy must issue a signed and dated power of attorney for the proxy. If the power of attorney is issued by a legal entity, a certified copy of registration certificate or equivalent document for the legal entity shall be presented. Any powers of attorney shall be in writing and submitted no later than at the AGM, but preferably by sending a copy thereof before that. The validity period of any power of attorney may be no longer than five years if set out specifically. If no validity period is specified, the power of attorney is valid for no more than one year. Forms for power of attorney can be found at the company’s website www.nexam.se and at the head office in Lund, (Medicon Village, Scheelevägen 2) and will be sent to shareholders who so request and state their address. Shareholders who have their holdings nominee-registered must temporarily register the shares in their own name to be entitled to participate in the AGM. Such temporary re-registration of ownership must be implemented no later than Thursday May 8, 2014. Accordingly, shareholders must inform their nominees or banks well in advance of that date of their wish to obtain temporary owner registration (so called voting-rights registration). Accounting documents and complete proposalsAccounting documents and complete proposals according to item 13-16 are available at the company’s head office in Lund and at the company’s website www.nexam.se no later than Wednesday April 23, 2014. Copies of the documents will upon request be sent to shareholders who state their address. Copies of the documents will also be available at the AGM. Duty of disclosure at the AGMShareholders are reminded of their right to request that the board and the CEO provide information pursuant to chapter 7, section 32 of the Swedish Companies Act. Agenda 1. Opening of the meeting 2. Election of Chairman of the meeting 3. Preparation and approval of the voting list 4. Approval of the agenda 5. Election of one or two persons to verify the minutes 6. Consideration of whether the meeting has been duly convened 7. Address by the CEO 8. Presentation of the Annual Report and Audit Report for 2013 and the Consolidated Annual Report and Consolidated Audit Report for 2013 9. Resolution ona) adoption on the profit and loss statement and balance sheet, as well as the consolidated profit and loss statement and consolidated balance sheetb) distribution of the company’s resultsc) discharge from liability for the Board members and CEO10. Determination of the number of Board members as well as the auditor and deputy auditor11. Determination of remuneration for the Board members and auditors12. Election of Board members as well as the auditor and deputy auditor13. Instruction for the Nomination Committee14. Adoption of Remuneration Policy15. Resolution on proposal for issuance of warrants and approval of transfer of warrants16. Authorization for issuing new shares17. Closing of the meeting Proposed resolutionsItem 2The Nomination Committee proposes that the Chairman of the Board, Lennart Holm, is appointed Chairman of the meeting. Item 9bThe Board proposes that no dividends are paid and that unappropriated earnings of SEK 243,112,000 are carried forward to a new account. Item 10The Nomination Committee proposes that four ordinary Board members without deputies are elected. The members are to be appointed until the next AGM. Further, the Nomination Committee proposes that a registered public accounting firm is appointed as auditor. The Nomination Committee proposes that the registered public accounting firm is elected until the next AGM. Item 11The Nomination Committee proposes that the remuneration paid to the Board is SEK 300,000, of which SEK 150,000 is remuneration to the Chairman and SEK 75,000 is remuneration to every other Board member who is not employed by the company. It is proposed that the remuneration for the auditor should be paid according to customary norms and approved invoice. Item 12The Nomination Committee proposes re-election of Lennart Holm, Michael Karlsson and Daniel Röme as ordinary board members. Further, the Nomination Committee proposes new election of Cecilia Jinert Johansson as ordinary board member. The Nomination Committee proposes re-election of Lennart Holm as Chairman of the Board. Per Palmqvist Morin has declined re-election. Information on the Board members proposed for re-election may be found in the Annual Report and at www.nexam.se.  Cecilia Jinert Johansson, born 1963, was until March 2014 head of production and head of EHSQ at Lantmännen division Lantbruk and has former i.e worked as Senior Vice President Operations at Ruukki Construction, in SVP Supply Chain Management for Rautaruukki Oyj and as Vice President Operations at Crawford Group. The Nomination Committee further proposes that Öhrlings PricewaterhouseCoopers AB is re-elected as accounting firm until the next AGM. Item 13Appointment of the Nomination Committee will take place before coming elections and payment of remuneration. It is proposed that the Nomination Committee should consist of three members, representing the two largest shareholders at the end of September together with the Chairman of the Board. Remuneration will not be paid to the members of the Nomination Committee. It is further proposed that instruction and charter for the Nomination Committee is adopted. Item 14The Board proposes that the AGM resolves to adopt guidelines regarding remuneration for the CEO and other senior executives in Nexam. The remuneration for the CEO and other senior executives may be fixed salary, pension, other benefits and share-based incentive programs. The guidelines means i.e that the CEO and other senior executives will be offered a fixed salary that is marketable. The remuneration of the CEO and other senior executives is based on factors such as work tasks, expertise, experience, position and performance. The CEO and other senior executives are entitled to annual pension contributions equivalent to 12 percent of the pensionable salary. A mutual notice period of six months for Nexam, the CEO and other senior executives and severance pay, in addition to salary, during the notice period may be up to a maximum of nine months' salary for the CEO and a maximum of 6 months for other senior executives. Item 15The Board proposes that the AGM resolves to implement an incentive program with warrants for senior executives and key persons in the company in accordance with the following: · A maximum of 1,083,849 warrants shall be issued. · With deviation from the shareholders’ preferential rights, the warrants may only be subscribed for by Nexam’s wholly owned subsidiary Nexam Chemical AB. Over subscription cannot occur. · Subscription shall be made at the latest on 31 October 2014, provided that the Board shall be entitled to prolong the subscription period. · The warrants shall be issued without consideration. The reason for issuing the warrants without consideration is that the warrants shall be utilized for implementation of Incentive Program 2014/2017. · Nexam Chemical AB shall have the right to, at one or several occasions, transfer warrants to senior executives and key persons in the Nexam group and to otherwise handle the warrants to fulfil the obligations under Incentive Program 2014/2017. Transfers to participants in Incentive Program 2014/2017 shall be made against cash consideration corresponding to the market value of the warrants calculated in accordance with the “Black Scholes” formula and accepted assumptions regarding among others volatility and risk free interest, which assumptions shall be based on measurements during the period 1 September 2014 – 12 September 2014 (the “Measurement Period”). · Each warrant confers right to subscribe for one new share in Nexam against cash payment at a subscription price corresponding to 150 per cent of the volume weighted average last closing price for Nexam’s share on Nasdaq OMX First North during the Measurement Period. The subscription price shall be rounded off to the nearest whole 10 öre, where 5 öre shall be rounded upwards. The subscription price and the number of shares that each warrant confers right to subscribe for shall be subject to customary recalculation formulas in connection with i.a. split, consolidation and rights issues. · The subscription right may be utilized during the period from and including 25 September 2017 to and including 9 October 2017. · The shares issued upon utilization of a warrant shall confer right to dividends as from the first AGM occurring after effectuation of the subscription. · The Board shall be entitled to resolve on transfer of warrants to senior executives and key persons in the Nexam group in accordance with the following guidelines:a) Key executives       at maximum 160,000 warrants per individual(apprx. 5)b) Key persons           at maximum 40,000 warrants per individual(apprx. 12) · Key executive who is also a member of the Board, shall not be entitled to participate in Incentive Program 2014/2017. · Notice of participation from key executives and key persons to participate in Incentive Program 2014/2017 shall have been received by Nexam at the latest on 30 September 2014, provided that the Board shall be entitled to prolong this time period and to apply a different notification period for participants that are subsequently employed in the Nexam group. · In case all warrants are exercised for subscription of new shares, the share capital will increase with SEK 20,843.250001. The reasons for the implementation of the warrant program with deviation from the shareholders’ preferential rights are to be able to create possibilities for Nexam to retain competent key persons through the offering of a long term ownership engagement for the key persons. Such ownership engagement is expected to stimulate the key persons to an increased interest in the business and profit development and increase the feeling of connectedness with Nexam. Nexam’s subsidiary Nexam Chemical AB has previously issued 7,280 warrants to employees. Each warrant confers right to subscription of one new share in the subsidiary at a subscription price of SEK 1,000 per share (4,340 warrants) and the subscription price of SEK 2,000 per share (2,940 warrants), respectively. The warrants can be utilized during the periods 15 September 2016 – 15 December 2016 (2,040 warrants), 15 September 2017 – 15 December 2017 (2,300 warrants) and 1 October 2018 – 31 December 2018 (2,940 warrants). Nexam has entered into agreements with the holder of the warrants pursuant to which Nexam has the right to acquire the shares potentially subscribed for against payment in the form of 182.5034 shares in Nexam for each new issued share in the subsidiary. In case all warrants are exercised for subscription of shares in the subsidiary, Nexam will issue 1,328,625 shares as consideration. The now proposed Incentive Program 2014/2017 and thereby associated issue of at maximum 1,083,849 warrants in accordance with the proposal above, may cause a dilution of approximately 2.0 per cent of Nexam’s share capital and votes after full dilution, calculated as the number of shares that will be added upon full exercise of Incentive Program 2014/2017 in relation to the number of existing shares with the addition of the shares that will be added upon full exercise of all warrants outstanding in the group. In case all warrants (existing as well as the now proposed) are exercised, the aggregate dilution, calculated in the same manner, will amount to approximately 4.45 per cent. Since the warrants in Incentive Program 2014/2017 will be transferred at market value, it is Nexam’s opinion that no social charges will be triggered for Nexam due to Incentive Program 2014/2017. The costs for Incentive Program 2014/2017 will hence only consist of limited costs related to implementation and administration of the program.Item 16The Board proposes that the AGM authorizes the Board, on one or several occasions until the next AGM, with or without deviation from the shareholders’ preferential rights, to resolve on new issues of shares. Issues may be made with or without the provisions regarding contribution in kind, set-off or other conditions. The number of shares that may be issued may not exceed a total of 5,753,333 shares (provided that such number of shares may be issued without amendment of the Articles of Association). The dilution may, upon full exercise of the authorization, amount to at the highest approximately 10 per cent. The purpose of the authorization is to enable to raise working capital, to enable to execute and finance acquisitions and to enable new issues to industrial partners within the framework of partnerships and alliances. To the extent the authorization is used for new issues with cash payment with deviation from the shareholders’ preferential rights, the issue price shall be on market terms. Particular majority decisionsValid resolution under item 15 requires that the proposals are supported by shareholders representing at least nine tenths of the votes submitted and represented at the AGM. Valid resolution under item 16 requires that the proposals are supported by shareholders representing at least two thirds of the votes submitted and represented at the AGM. Number of shares and votesAs of the date of issuing of this notice to attend, the total number of registered shares and votes in the company amounts to 51,780,000. The company holds no own shares.Lund, April 2014 Nexam Chemical Holding AB (publ)The Board of Directors Note: This press release has been translated from Swedish. The Swedish text shall govern for all purposes and prevail in case of any discrepancy with the English version.

Researchers transplant regenerated oesophagus

The new method has been developed by researchers at Karolinska Institutet in Sweden, within an international collaboration lead by Professor Paolo Macchiarini. The technique to grow human tissues and organs, so called tissue engineering, has been employed so far to produce urinary bladder, trachea and blood vessels, which have also been used clinically. However, despite several attempts, it has been proven difficult to grow tissue to replace a damaged oesophagus. In this new study, the researchers created the bioengineered organs by using oesophagi from rats and removing all the cells. With the cells gone, a scaffold remains in which the structure as well as mechanical and chemical properties of the organ are preserved. The produced scaffolds were then reseeded with cells from the bone marrow. The adhering cells have low immunogenicity which minimizes the risk of immune reaction and graft rejection and also eliminates the need for immunosuppressive drugs. The cells adhered to the biological scaffold and started to show organ-specific characteristics within three weeks. The cultured tissues were used to replace segments of the oesophagus in rats. All rats survived and after two weeks the researchers found indications of the major components in the regenerated graft: epithelium, muscle cells, blood vessels and nerves. “We believe that these very promising findings represent major advances towards the clinical translation of tissue engineered esophagi”, says Paolo Macchiarini, Director of Advanced center for translational regenerative medicine (ACTREM) at Karolinska Institutet. Tissue engineered organs could improve survival and quality of life for the hundreds of thousands of patients yearly diagnosed with oesophageal disorders such as cancer, congenital anomalies or trauma. Today the patients’ own intestine or stomach is used for esophageal replacements, but satisfactory function rarely achieved. Cultured tissue might eliminate this current need and likely improve surgery-related mortality, morbidity and functional outcome. The current study was conducted in collaboration with the Texas Heart Institute in the U.S., as well as universities in Italy, Russia, and Germany. It was supported financially by, among others, the Swedish Research Council, the Stockholm County Council through the ALF agreement, and the European Union’s Seventh Framework Programme. The equipment used in the study was developed by the company Harvard Apparatus Regenerative Technology. Publication: ‘Experimental orthotopic transplantation of a tissue-engineered oesophagus in rats’, Sebastian Sjöqvist, Philipp Jungebluth, Mei Ling Lim, Johannes C. Haag, Ylva Gustafsson, Greg Lemon, Silvia Baiguera, Miguel Angel Burguillos, Costantino Del Gaudio, Alexander Sotnichenko, Karolina Kublickiene, Henrik Ullman, Heike Kielstein, Peter Damberg, Alessandra Bianco, Rainer Heuchel, Ying Zhao, Domenico Ribatti, Cristián Ibarra, Bertrand Joseph, Doris A. Taylor & Paolo Macchiarini, Nature Communications (http://www.nature.com/ncomms/index.html), online 15 April 2014, doi:10.1038/ncomms4562.

PR and Digital Marketing Agency lotus823 Appoints Nancy Kohlreiter as Director of Business Development and Operations

EATONTOWN, N.J. – lotus823, a PR and digital marketing agency based in New Jersey, is pleased to announce the recent appointment of Nancy Kohlreiter as Director of Business Development and Operations. In her new role, Kohlreiter will lead the Business Development team, utilizing her 13 years of experience in merchandising to foster new business relationships for the company. Additionally, she will head operations at lotus823, where she will advise and guide the management team to better streamline internal processes as the company continues to scale. Leveraging her work in product development, Kohlreiter’s retail and vendor experience will also add value to lotus823’s branding consultancy services. “I’ve had the opportunity to work with Nancy in various capacities over the last 10 years and I’m thrilled to have her as part of our team at lotus823,” said David Hernandez, Managing Partner, lotus823. “Nancy’s business acumen and track record for building strategic partnerships will be a driving force in lotus823’s continued growth.” Before joining lotus823, Kohlreiter was the Senior Director of New Product Acquisition at Office Depot where she specialized in buying, category development, new category development, and new business development. Her expertise in consumer products and how they relate to the marketplace makes her a valuable asset to the PR and digital marketing agency (http://www.lotus823.com/). “I’m excited to join lotus823’s dynamic team,” said Nancy Kohlreiter. “I’ve worked with the company’s co-founders Allison and David Hernandez for many years, and I’ve always admired lotus823’s impressive growth and innovative ideas. I look forward to working with their phenomenal team of creative, effective marketing executives.”

PA Resources' Interim Report 1 January – 31 March 2014

FIRST QUARTER · Group revenue totalled SEK 178 million (359) · EBITDA was SEK 114 million (211) · Profit after tax was SEK -48 million (34) · Earnings per share were SEK -0.43 (1.57) KEY EVENTS · Successful long term drilling test carried out on Diega – pilot well encountered oil · The Mer Profonde Sud farm-out received governmental approval · Working capital facility of USD 50 million signed with Gunvor SUBSEQUENT EVENTS · Nomination committee proposes new Chairman and new board member · Uncertainty and delays in the farm-out process in Tunisia FINANCIAL KEY RATIOS   January - March Full year 2014 2013 2013Average production, barrels/day 3,400 6,800 4,600Revenue, SEK million 178 359 1,049EBITDA, SEK million 114 211 -494EBITDA margin, % 64% 59% negOperating profit, SEK million 71 117 -1,234Profit for the period, SEK million -48 34 -1,219Earnings per share after dilution, SEK -0.43 1.57 -21.54 For the complete Interim Report, see attached file. WEBCAST PA Resources' results for the first quarter of 2014 will be presented on 16 April 2014 at the Annual General Meeting. An on-demand webcast will be available on PA Resources’ website www.paresources.se after the AGM. CONTACT Queries concerning this report can be directed to: Tomas Hedström, CFO +46 8 545 211 50 ir@paresources.se Mark McAllister, President and CEO +46 8 545 211 50 ir@paresources.se Disclosure The information in this interim report is such that PA Resources AB is required to disclose pursuant to the Securities Market Act and Financial Instruments Trading Act. Submitted for publication at 07:30 a.m. (CET) on 16 April 2013. PA Resources in brief PA Resources AB (publ) is an international oil and gas group that conducts exploration, development and production of oil and gas assets. The Group operates in Tunisia, the Republic of Congo (Brazzaville), Equatorial Guinea, the United Knigdom, Denmark, the Netherlands and Germany. PA Resources is producing oil in West Africa and North Africa. The parent company is located in Stockholm, Sweden. PA Resources’ shares are listed on NASDAQ OMX in Stockholm, Sweden. For further information, please visit www.paresources.se.

Notice of Annual General Meeting of Proffice Aktiebolag

PRESS RELEASE                                                                   Stockholm, April 16 2014 Shareholders in Proffice Aktiebolag (publ), corporate identity no. 556089-6572 (“the Company”), are hereby invited to attend the Annual General Meeting (AGM) on Thursday, 22 May 2014 at 3 pm at Proffice’s headquarters, Regeringsgatan 65 in Stockholm, Sweden. Notice of intention to participate Shareholders who wish to participate in the AGM must: · Be registered with Euroclear Sweden AB by 16 May 2014, and · Send notification to the Company to be received before 4 pm on Friday, 16 May 2014 to one of the following: Proffice AB (publ), Shareholder Service, PO Box 70368, SE-107 24 Stockholm, Sweden, or by telephone: +46 8-787 17 00 or e-mail: ir@proffice.com . When registering, shareholders must include their name, address, telephone number, civil identification or corporate identity number, the number of shares represented, and the names of any legal representatives. If participation is by proxy, the proxy form must be submitted prior to the AGM. Proxy forms in Swedish and English are available on the Company’s website at; www.proffice.com. Shareholders whose shares are registered under a nominee name must temporarily re-register them in their own names, in addition to registering their intention to participate in the AGM. For such registration to be completed by Friday, 16 May 2014, shareholders should contact their banks or nominees well in advance. Business and proposed agenda 1. Opening of the AGM and election of chairman for the meeting.2. Preparing and approving voting list.3. Approving the agenda.4. Electing at least one person to verify the minutes.5. Considering whether the AGM was duly convened.6. Presenting the annual report, auditors’ report, consolidated accounts, and consolidated auditors’ report (the CEO will submit a statement on operations under this item).7. Resolutions a) Adopting the income statement, balance sheet, consolidated income statement, and consolidated balance sheet. b) Appropriating the Company’s profit/loss per the adopted balance sheet. c) the discharge of the members of the Board and the CEO from liability.8. Determining the number of board members.9. Determining board remuneration and auditors’ fees.10. Informing as per Chapter 8, Section 48 of the Swedish Companies Act on positions held by proposed board members in other companies.11. Electing the board and auditor.12. Determining remuneration guidelines for senior executives.13. Authorising the board to make decisions on new share issues.14. Authorising the board to make decisions on acquisitions and assignment of Company shares.15. Closing the meeting. Resolution proposals Item 7b. The Board’s proposal for distribution of profits The Board of Directors proposes dividend for 2013 of SEK 0.60 per share. The board proposes a record date of 27 May 2014 for the dividend. If the proposal is approved at the AGM, the dividend is expected to be paid by Euroclear Sweden AB on Thursday, 2 June 2014. Items 8 – 9 and 11 Nomination Committee’s proposal The Nomination Committee, consisting of Joakim Rubin (chairman), CapMan Public Market Fund, Marianne Flink, Swedbank Robur fonder, Jan Särlvik, Nordea Investment Funds, Frank Larsson, Handelsbanken Fonder AB and Hans Hedström, Carnegie fonder, propose the following to the AGM: (i) that Lars Murman is appointed chairman of the AGM. (ii) that the board of directors consists of six (6) members elected by the AGM. (iii) re-election of Cecilia Daun Wennborg, Karl Åberg, Lars Johansson and Susanna Marcus to the board of directors, until the end of the next AGM. Lars Murman and Karin Eliasson have declined re-election. The Nomination Committee proposes that the AGM elects Axel Hjärne and Juan Vallejo as new members of the board of directors until the end of the next AGM. Axel Hjärne, 49 years old, is since 2009 President and CEO of Eltel Group. Axel was previously COO and Deputy CEO of Bravida Group and before that held management positions in ABB. Axel is the Deputy Chairman in Prima Barn- och Vuxenpsykiatri. Axel has a Master of Science in Engineering from the Institute of Technology, Linköping University. Shares in Proffice : 0Independent of the company, its management and major shareholders. Juan Vallejo, 56 years old, is since 2011 CEO of Imtech Nordic. Juan was previously President and CEO of Niscayah Group and before that held management positions in Securitas where he was a member of group management 1992-2006. Juan is a board member in Coromatic Group. Juan has a Master of Science in Engineering from KTH Royal Institute of Technology. Shares in Proffice: 0Independent of the company, its management and major shareholders. (iv) election of Cecilia Daun Wennborg as chairman of the board of directors until the end of the next AGM. (v) that fees are paid to the board of directors with SEK 570,000 to the chairman of the board and SEK 265,000 to each of the other elected board members. In addition, the Nomination Committee proposes that fees for committee work are paid with SEK 80,000 to the chairman of the Audit Committee and SEK 25 000 to the other elected members of committees. The chairman of the board does not receive remuneration for committee work. (vi) The Nomination Committee proposes election of the registered auditing company PricewaterhouseCoopers AB as auditor of the Company for a period of time of three years with the authorized auditor Nicklas Kullberg as the principal auditor. (vii) The nomination committee proposes that remuneration to the auditor should be paid as per approved account. (viii) The Nomination Committee proposes a change in the instruction for the Nomination Committee, whereby the number of shareholder representatives is changed from five to four. Otherwise the instruction shall remain unchanged. New wording is; Instruction for the Nomination Committee The Nomination Committee also proposes these principles for electing Nomination Committee members: -       The Company is to have a Nomination Committee comprising one representative from each of the four largest shareholders. If any shareholder waives its right to appoint a representative, the next shareholder with the largest number of votes shall appoint a representative. The names of the four owner representatives and the names of the shareholders they represent shall be announced on the Company’s website no later than six months before AGM. The Nomination Committee shall be elected based on shareholder statistics from Euroclear Sweden AB at the last banking day in August and other reliable owner information that has been received by the Company as of this date. The Nomination Committee’s term of office extends until a new committee is appointed. Unless members agree otherwise, the Nomination Committee chairman is to be the member who represents the shareholder with the most votes. The majority of Nomination Committee members shall not also be board members. -       If, during the Nomination Committee’s term of office, one or more of the shareholders who appointed members to the Nomination Committee are no longer among the four largest shareholders, the members appointed by these shareholders shall resign and the shareholder or shareholders who have become one of the four largest shareholders shall appoint their own representatives. Unless there are special circumstances, no changes will be made in the composition of the Nomination Committee if there are only minor changes in the number of votes held, or if the change occurs later than two months before the AGM. Shareholders that appoint Nomination Committee members are entitled to discharge such members and appoint new members. If a member leaves the Nomination Committee before its work is completed, the shareholder who appointed the member shall be entitled to appoint a replacement. Changes in the composition of the committee shall be published on the company’s website as soon as they occur. -       The Nomination Committee shall develop and submit proposals to AGM for: (a)   proposed board members (b)   proposed board chairman (c)   proposed board fees for non-employed board members, distinguishing between the chair and other members of the board, proposed committee remuneration, (d)   where applicable, proposed auditor (e)   proposed audit fees, and (f)    proposed AGM chair, and (g)   to the extent deemed necessary, changes to this instructions for Nomination Committee. Proposals will be published in the AGM notice and on the company’s website. -       Information on how shareholders can submit proposals to the Nomination Committee shall be specified on the company’s website. -       Along with its other assignments, the nomination committee shall perform the duties required of it by the Swedish Code of Corporate Governance, and, at the request of the Nomination Committee, the company shall provide personnel resources such as secretarial functions to facilitate the committee’s work. When necessary, the company shall also assume reasonable costs for external consultants as the Nomination Committee deems necessary for fulfilling its duties. -       That these instructions for the Nomination Committee will apply until further notice. Item 12. Board’s proposal regarding guidelines for remuneration to senior executives The board proposes that the following unchanged, in principal, guidelines for remuneration of senior executives be approved at the 2014 AGM. The Company shall offer market-adjusted total compensation that enables it to recruit and retain senior executives. Senior executives are defined as those who report directly to the CEO and has the authority and responsibility for planning, directing and controlling of the Group and those who report directly to the CEO and are responsible for earnings. Remuneration of the CEO and other senior executives constitutes a fixed salary and a variable component. The fixed component consists of salary, pension benefits and other benefits, such as a car allowance. The variable salary component can include short- and long-term portions. A maximum limit shall be imposed on the short-term variable salary component for the CEO and other senior executives and must never exceed the fixed salary. Senior executives with performance accountability are entitled to participate in the company’s long-term incentive program, which may be cash- or share-based. Cash-based programs shall be limited to six (6) monthly salaries per annum for all except the CEO, whose program is limited to sixteen (16) monthly salaries per annum. The variable salary component is mainly based on financial targets, taking into account the cost of any bonuses; that is, the bonus shall be self-financed. Retirement age is 65. Retirement benefits for senior executives shall be adapted to location and market. For the CEO, the company annually sets aside 30 per cent of the CEO’s pensionable annual salary for pension and insurance solutions. The company shall accept a salary reduction plan as pension contribution under the condition that it is cost-free for the company. The CEO’s period of notice is 12 months on the company’s part and 12 months on the CEO’s part. In addition, if the company gives notice of termination, the CEO is entitled to severance pay amounting to one year’s salary. For other senior executives, the notice of termination is 12 months maximum on the company’s part and 6 months on the employee’s part. The board may make exceptions to these guidelines if, in an individual case, there is reason to do so. Proffice has followed the AGM 2013 the guidelines adopted for remuneration to senior executives but the Board has, in accordance with what is permitted by the guidelines, deviated from the guidelines in the sense that the CEO entered into an employment agreement with six months' notice of termination by his side. Further, in 2014, the CEO is entitled to a guaranteed bonus of six months' salary. The deviations are motivated by market factors. Item 13. Board’s proposal to authorize the board to issue new shares The board proposes that the shareholders give the board the authority until the next AGM to, on one or more occasions, decide on new share issues of up to 3,500,000 series B shares with or without preferential rights to shareholders, denoting an increase in the company’s share capital of no more than SEK 875,000. New shares will be issued as needed to implement or finance acquisitions of all or parts of other companies or operations. Besides cash, payment for shares will be made in kind or offset as per chapter 13, section 5, paragraph 6 of the Swedish Companies Act. 5 § 6 p. The Swedish Companies Act. In each case, the issue price will be set as near the market value as possible. It is also proposed that the AGM authorize the board or CEO to make minor adjustments to the above resolution that may be required in connection with registration of the resolution with the Swedish Companies Registration Office. Item 14. The board’s proposal authorising the board to make decisions on acquisition and assignment of company shares a)     Authorising the board to make decisions on acquisitions of its own B shares on NASDAQ OMX Stockholm. The board proposes that the AGM authorises the board to, for one or more occasions until the 2015 AGM, make decisions on the acquisition of own shares as follows: · Acquisition of own B shares shall be from NASDAQ OMX Stockholm. · Acquisition of own B shares may occur such that the Company holdings of own shares amounts to no more than one-tenth of all shares in the company. · Acquisition of own B shares shall be at a price within the current price interval on the Exchange at the time of acquisition. b)    Authorising the board to make decisions on acquisitions of its own shares as per acquisition propositions to shareholders The board proposes that the AGM authorises the board to, for one or more occasions until the 2015 AGM, make decisions on the acquisition of own shares as follows: · Acquisition of own shares may occur such that the Company holdings of own shares amounts to no more than one-tenth of all shares in the company. · Acquisition of shares through acquisition propositions directed to company shareholders may occur at an acquisition price that exceeds the current market price. The aim of the proposed buyback opportunities in a) and b) is to give the board additional space in which to act in conjunction with possible future company acquisitions and increased opportunities to regularly adapt the company's capital structure, thereby promoting increased shareholder value. c)     Authorising the board to make decisions on transfer of its own B shares on NASDAQ OMX Stockholm in conjunction with company acquisitions · Transfer of own B shares may be on NASDAQ OMX Stockholm or with other methods. · Transfer of own B shares may deviate from shareholder preferential rights. · No more than the number of B shares held by the Company at the time of the Board decision to transfer shares may be transferred. · Transfer of own B shares shall be at a price to be determined in close connection to the rates on the exchange at the time of the Board’s decision on transfer. · Payment for the own B shares transferred shall be able to be via cash, capital contributed in kind, or via receivables. The aim of the proposed transfer opportunities and the possible deviation from shareholder preferential rights is to give the Board increased manoeuvring space in conjunction with any future company acquisitions by facilitating quick, cost-effective financing opportunities. Finally, the Board proposes that the AGM authorize the board or CEO to make minor adjustments to the above resolutions a-c that may be required in connection with implementing the decision. Majority requirements A valid resolution as per the board's proposals in items 13 and 14 requires that said resolution is supported by at least two-thirds of the votes cast and shares represented at the AGM. Number of shares and votes When this notice was issued, the total number of shares in the company was 68,677,773, of which 2,000,000 A shares with 10 votes each and 66,677,773 B shares with one vote each. The Company holds, as of the same date, 438,919 own B shares, representing 0.51 per cent of votes, that can not be represented at the general meeting. Disclosures at the AGM The Board and CEO shall, by shareholder request, disclose information at the AGM concerning conditions that could affect the assessment of an item on the agenda, the Company’s financial situation, or a subsidiary’s financial situation, or the Company’s relationship to another Group company, provided that the Board deems that disclosure is possible without causing material damage to the Company. Questions may be submitted in advance to Proffice Aktiebolag (publ), att: Manager Legal Department, Box 70368 SE-107 24, Stockholm Sweden. Documents The annual accounts, auditor’s report, auditor statement as per Chapter 8 Section 54 of the Companies Act, and the Board statement as per Chapter 18 Section 4 and Chapter 19 section 22 of the Companies Act, will be available at the Company and published on the Company’s website (www.proffice.com) no later than 16 April 2014, and will be sent on request to shareholders who provide an address. Stockholm, April 2014Proffice Aktiebolag (publ)Board of Directors For more information, contact: Henrik Höjsgaard, CEO, Proffice AB, +46 8 787 17 00, henrik.hojsgaard@proffice.comBenno Eliasson, CFO, Proffice AB, +46 8 787 17 00, benno.eliasson@proffice.com Proffice is the specialised flexible staffing company with more than 10,000 employees in the Nordic region. We provide temporary staffing, recruitment services, and outplacement. Proffice is listed on the NASDAQ OMX Stockholm, Mid Cap. www.proffice.com Proffice Aktiebolag discloses the information provided herein pursuant to the Securities Markets Act. The information was submitted for publication at 8 am CET on April 16 2014.

D. Carnegie & Co and HBS II has initiated negotiations regarding a merger of their property portfolios

The Company will, if the parties reach a final agreement and the transaction is completed, be the largest listed specialised residential real estate company. The negotiations are conducted with a common ambition between the parties to reach a binding agreement during May, 2014. D. Carnegie & Co will return with more detailed information about the transaction as soon as a binding agreement has been entered into. The intention is that the transaction is effectuated by merging HBS II’s properties with D. Carnegie & Co’s. Through the transaction, the current owners of HBS II will remain as significant owners in the accumulated property portfolio in D. Carnegie & Co. A final agreement is subject to, inter alia, approval from the board of directors of both companies, and that both companies are entitled to carry out a due diligence review of the properties and that nothing materially adverse emerges from such investigations. Furthermore, the transaction will require that shareholders’ meetings are summoned in HBS II’s two holding companies and D. Carnegie & Co to resolve upon amendments of the articles of association and an issue of securities. The complementing operations of both companies sets out a beneficial starting point for a continued common development of the Company and the boards of directors of both companies considers the transaction to constitute a major opportunity for their respective shareholders. D. Carnegie & Co currently maintains its internal property management organisation through Stendörren and HBS II has its own organisation for property management, Graflunds AB. After the transaction, the intention is that the management of all properties is co-ordinated. D. Carnegie & Co has a highly efficient and cost-saving renovation model in Bosystem™, where the apartments are refurbished  in connection with the natural turnover of tenants. Bosystem™ will continue to be the core in the improvement of the Company’s real estate portfolio and thereby continue to create substantial value in the integrated portfolio. Ulf Nilsson, VD, comments: “Given our ambition to grow substantially on our core market, this is a fantastic opportunity to reach and exceed our growth targets. After completion of the transaction, we will look into the portfolio with the intention to streamline the geographical location of our properties”. About D. Carnegie & Co D. Carnegie & Co is a real estate company focusing on residential properties within the Stockholm region and other growth areas. The Company’s business concept is to own and manage its real estate portfolio and to gradually refurbish apartments in connection with the natural turnover of tenants. This can take place quickly and cost-efficiently due to the Company’s established refurbishment method, BosystemTM. The refurbishment model is popular with both tenants and the Swedish Union of Tenants (Sw. Hyresgästföreningen) as the apartments are attractively refurbished without any tenants being forced to vacate the premises against their will. At the beginning of 2014, Stendörren transferred its residential properties to D. Carnegie & Co and thereby became the owner of a real estate portfolio consisting of residential properties in Stockholm’s growth areas. As of 31 December 2013, the market value amounted to SEK 2,929 million and the total rental value was estimated to SEK 287 million per year. The financial leasing rate is high and none of the properties are vacant. D. Carnegie & Co’s real estate portfolio is situated in the Stockholm region. D. Carnegie & Co is listed on NASDAQ OMX First North as of April 9, 2014. About Hyresbostäder i Sverige II ABHBS II has since 2004 been an sizeable participant in the Swedish residential property market with a portfolio of over 700,000 sqm of residential area. The properties are located in Eskilstuna, Strängnäs, Södertälje, Huddinge, Haninge, Bro, Märsta, Uppsala och Göteborg. HBS II has an own property management organisation, Graflunds AB, which manages all HBS II’s properties and also external properties.  HBS II is owned by Norwegian and Swedish investors through Boligutleie Holding II AB and Hyresfastigheter Holding II Blå AB. According to the investment mandate, the property portfolio will be disposed of between 2013 and 2016, depending on most optimal market conditions. For further information, please contact: Ulf Nilsson, CEO, D. Carnegie & Co AB +46 (0)8 121 317 00 Knut Pousette, Chairman of the Board of Directors, D. Carnegie & Co AB +46 (0)8 121 317 00 Further information is available on www.dcarnegie.se

Balder Acquires a Hotel Portfolio for SEK 2,2 billion

Balder (publ) has agreed to acquire a hotel portfolio of 14 hotel properties from Pandox. The purchase price amounts to SEK 2,2 billion and covers 127,000 sq m and 2,400 hotel rooms. Over 40 % of the assigned property value is situated in the Stockholm region and the remaining values are situated in cities as Gävle, Karlstad and Lund where Balder already have local representation.Scandic is the single largest tenant, representing 65 % of the earnings, Nordic Choice represents 20 % and Winn Hotel Group 12 %. The leases have a remaining average term of approximately 7 years. The properties will be taken into possession in the second quarter of 2014."We are delighted to make this acquisition with Pandox. I would also like to thank Christian Ringnes and Olaf Gauslå for a professional, easy and pleasant approach to complete this transaction," said CEO Erik SelinPangea has facilitated the deal between the parties. For further information, please contactCEO Erik Selin, phone 0706-07 47 90 orHead of Finance Marcus Hansson, phone 0768-36 98 48 Fastighets AB Balder (publ) discloses the information provided herein pursuant to the Swedish Securities Markets Act and/or the Swedish Financial Instruments Trading Act. The information was released for publication on 16 April, 2014 at 08.15 CEST. Fastighets AB Balder (publ)Box 53121, 400 15 GothenburgPhone 031-10 95 70Org nr 556525-6905, Gothenburgwww.balder.se Fastighets AB Balder is a listed real estate company which shall meet the needs of different customer groups for premises and housing through local support. Balder's real estate portfolio had a value of SEK 27.5 billion as of 31 December 2013. The Balder share is listed on Nasdaq OMX Stockholm, Mid Cap.

ICA Gruppen sells Kjell & Company, capital gain c. SEK 440 million

ICA Gruppen has signed an agreement with FSN Capital to sell its 50% holding in Kjell & Company for a cash consideration of SEK 630 million. The capital gain is expected to amount to approximately SEK 440 million after deduction for costs and will be recognised in the second quarter of 2014. ICA Gruppen’s CEO, Per Strömberg, comments: “The divestment of Kjell & Company is in line with the plan we presented in November last year which means that we are focusing our non-food offering. This is a good moment for a change of ownership in Kjell & Company.” Last year, ICA Gruppen performed an evaluation of the portfolio companies in parallel with the formulation of a new non-food strategy for the Group. As a result of this evaluation it was decided to initiate a divestment process for Kjell & Company. In the year-end report for 2013 the holding in Kjell & Company was recognised among assets held for sale. ICA Gruppen, formerly Hakon Invest, has been an owner of Kjell & Company since 2006, when 50% of the company was acquired from the founders. Since this investment was made, Kjell & Company has grown from 15 stores with annual sales of SEK 255 million to 74 stores with annual sales of SEK 931 million in 2013. In conjunction with this transaction, the other shareholders will sell shares in Kjell & Company on the same terms as ICA Gruppen. The founders will remain as significant owners of the company. The sale, which is subject to approval from the Swedish Competition Authority, is expected to be completed in the second quarter of 2014. For more informationICA Gruppen’s press service, telephone: +46 10 422 5252 ICA Gruppen AB discloses the information provided herein pursuant to the Swedish Securities Market Act and/or the Swedish Financial Instruments Trading Act. The information was submitted for publication at 08.30 CET on Wednesday, 16 April 2014.

Pandox sells 14 hotel properties

Pandox has sold a portfolio which comprises 14 Swedish hotel properties with a total of 2 400 rooms to Fastighets AB Balder. The total purchase price is SEK 2.2 billion. The buyer will assume ownership of the properties during the second quarter of 2014. The hotels included in the portfolio are: · Best Western Royal Corner Växjö, 159 rooms · Clarion Hotel Plaza Karlstad, 131 rooms · Park Inn by Radisson Solna, 247 rooms · Quality Hotel Grand Kristianstad, 137 rooms · Quality Hotel Nacka, 164 rooms · Scandic Gävle Väst, 200 rooms · Scandic Skogshöjd Södertälje, 225 rooms · Scandic Star Lund, 196 rooms · Scandic Swania Trollhättan, 201 rooms · Scandic Uplandia Uppsala, 133 rooms · Scandic Upplands Väsby, 156 rooms · Scandic Uppsala Nord, 184 rooms · Scandic Västerås, 174 rooms · Scandic Växjö, 123 rooms Pandox is one of the leading players in the European hotel property market as regards geographical spread, number of hotels, brand names and size. After the divestment, the Pandox portfolio will comprise 105 hotel properties, one congress centre and 16 hotel operations with a total of 22 000 rooms in nine countries. The hotels are run under various types of leases, either under well-known brands such as Scandic, Hilton, InterContinental, Hyatt, Radisson Blu, Crowne Plaza, Holiday Inn, Clarion, Comfort, Quality, Elite, First, Rica, Best Western, Rantasipi and Omena or through independent distribution channels. Pandox AB (publ) is owned by Eiendomsspar AS, CGS Holding AS and Helene Sundt AS. For further information, please contact:   Anders Nissen                    CEO Pandox AB (publ)        +46 (0)8 506 205 50+46 (0)708 46 02 02anders.nissen@pandox.se Liia Nõu CFO Pandox AB (publ) +46 (0)8 506 205 80+46 (0)70 237 44 04 liia.nou@pandox.se

Kungsleden letting 7,900 sq.m. in Karlstad

Nordicwheels will relocate to the property designated Östanvinden 4 on 1 August 2014, and into the premises that Sweden Post Logistics vacated at the end of March this year. This property is in the largest industrial and logistics estate in Karlstad, which lies on the main highways and only 5 km from the centre of the city. The premises are well suited to Nordicwheels’ operations, with only very few adaptations required.Additionally, well-known Lebanese restaurant Pasha has decided to relocate from the city centre to Örsholmen, and has signed a ten-year contract.Other current tenants in this property include the County Council, Emmaboda glas and Stena metall.“We’ve succeeded in the filling a very substantial vacancy very quickly and are delighted to be able to offer expedient premises for Nordicwheels’ start-up in Karlstad,” commented Anders Frisell, Kungsleden’s Assistant Property Manager.Pasha restaurant will relocate its operations from the former premises in the centre of Karlstad, which are to be demolished and converted to housing. Kungsleden will be adapting and modernising these premises for the relocation, which is scheduled for 1 October 2014.“Pasha is a popular luncheonette and exactly the right tenant for these premises and the property. The restaurant will make a positive contribution to the services available in the estate, enhancing the attractions of the property and the estate for current and potential tenants,” continued Mr. Frisell.

Falken race team’s rapid turnaround leads to VLN podium joy

After a serious accident at the end of the Nürburgring’s Döttinger Höhe straight severely damaged Falken’s Porsche GT3R, the odds were heavily stacked against its race team to return for the next VLN race the following weekend. What started as a nightmare ended in a dream as not only did it manage to compete, but the Falken drivers Martin Ragginger and Alexandre Imperatori, out for the first time in the car, also recorded the team’s first podium finish in the VLN series just a week later.The recovery process started on Monday: Representatives from Falken’s headquarters in Japan, its European headquarters in Germany, race team manager Sven Schnabl and the Porsche Motorsport department convened to see if it was feasible to field a car in the next race. In the back of everyone’s mind was the need to test new tyres before the 24-hour race. With time running out ahead of the June enduro, everyone agreed all opportunities had to be seized. With insufficient time to repair the existing car, the answer was a fresh chassis from Porsche. By luck a GT3 spec 997 was in stock and after the deal was completed on Tuesday, the Schnabl trailer was dispatched and a new, plain white GT3R was picked up direct from Weissach the following day. The entire Schnabl team toiled all night and by Thursday morning, the ‘stock’ GT3 was transformed into a VLN spec racer, set up for the Nordschleife. Come 12 o’clock on Friday, the car was rolled out in Falken’s iconic colours and incredibly, was ready for qualifying. "In order to be best prepared for the 24-hour race, we have to go to every possible race. I am therefore pleased that the decision to participate in the second VLN race was taken and then everything came together so quickly," says team manager Sven Schnabl, "Through our good connections with Porsche, we could get a replacement car in no time. This definitely made up for the disappointment the weekend before”. Takeshi Imakita, chief tyre engineer for the Falken team, adds: "I am appreciative that we have the support of Porsche and that due to the tireless efforts of Schnabl Engineering we’ve been able to race at all this weekend! The disappointment last weekend was immense, but now we can get back on track with our development programme, invigorated by our first podium.The successful pairing of Martin Ragginger and Alexandre Imperatori will line up again for Falken at the next VLN race in the series, the DMV 4 –hour at the end of the month. # About FALKEN Tyre Europe: The technology and development of Falken High Performance Tyres and their driving characteristics have, for many years, been derived from motorsport, most recently its participation in the Tudor United Sportscar Championship and Nürburgring 24 Hours. Tyre technologies developed on track are often transferred to the road, offering improvements in wet and dry grip, efficiency, feeling and control. Falken Tyre Europe is a brand of Sumitomo Rubber Industries Japan, with European headquarters near Frankfurt. Falken has aggressively expanded its product range, launching new products in new sectors and niches across Europe. Falken’s current products range from the track-inspired Azenis series including the latest FK453 flagship through to the efficient and innovative ZE914, the rugged all-terrain WildPeak A/T, cold weather HS449 and SN832 Ecorun. All FALKEN products fulfil ISO standards 9001 and 14001. For more information visit www.falken-europe.de or www.facebook.com/falkenmotorsports Falken tyres are produced to the highest-quality standards – all production facilities are ISO9001: 2000 and ISO / TS 16949:2002 certified. Additionally, all factories have certification under the ISO14001 Environmental Management System. # Pressekontakt Unternehmen: FALKEN Tyre Europe GmbH, Nadine Cerone Tel.: 069-247 52 52 – 64,Fax: 069-247 52 52–11, E-Mail: n.cerone-schatz@falken-europe.de For UK press enquiries: Propel Technology, Nick Bailey, Tel: +44 (0) 1295 770602, email nick@propel-technology.com

Announcement from PA Resources’ AGM on 16 April 2014

The annual report for the parent company and the consolidated group’s annual report, together with the auditor’s report for the fiscal year 2013, were presented. The income statement and the balance sheet for both the parent company and the group regarding the fiscal year 2013 were adopted by the meeting. The Meeting decided that no dividend would be paid out for the fiscal year 2013. The members of the Board and the CEO were granted discharge from liability for the fiscal year 2013. The Meeting decided that the Board would comprise six ordinary members and re-elected Paul Waern, Philippe R Probst, Philippe R Ziegler and Nils Björkman and elected the company’s CEO Mark McAllister and Jérôme Schurink as new members. Jérôme Schurink was elected Chairman of the Board. The Meeting decided to re-appoint Ernst & Young as auditors with the chartered accountant Björn Ohlsson as head auditor. The fees to the Board of Directors were determined by the Meeting to a total of SEK 1,650,000 (last year 1,650,000) with SEK 550,000 to the chairman (last year 550,000) and SEK 275,000 to each of the other members not employed by the company (last year 275,000). The fees to the auditors would be paid according to reasonable and by the Company approved invoice. The Meeting decided to establish a Nomination Committee for the next AGM, whereby three largest shareholders in Company as per 30 September 2014 will be asked to appoint one representative each, who together with the Chairman of the Board will comprise the Nomination Committee. In the event that a shareholder does not appoint a member, the next largest shareholder will be asked. The composition of the Nomination Committee must be communicated at the latest six months before the AGM in 2015. The Meeting approved the guidelines proposed by the Board regarding remuneration to the CEO and other senior executives. The CEO of PA Resources, Mark McAllister, addressed the Meeting and reported on the Group’s development during the fiscal year 2013 and the first quarter 2014. The presentation is available on the company’s website www.paresources.se. Stockholm, April 16, 2014 PA Resources AB (publ) For further information, please contact: Ingrid Östhols, Head of Corporate Communication and IR Tel +46 721 810 86 ir@paresources.se The above information has been made public in accordance with the Securities Market Act and/or the Financial Instruments Trading Act. The information was published at 12.30 pm CET on 16 April 2014.

Getinge Group Interim Report January - March 2014

Reporting period January – March · Order intake increased 0.2% to SEK 5,977 M (5,968), and grew 0.3% organically. · Net sales declined 0.6% to SEK 5,632 M (5,664), and fell 0.4% organically. · The result before tax declined to a loss of SEK 452 M (252). Adjusted for the provision of SEK 799 M for consulting efforts to strengthen the quality management system within Medical Systems, profit before tax rose 37.7% to SEK 347 M. · The net profit declined to a loss of SEK 330 M (148). Adjusted for the provision of SEK 799 M for consulting efforts to strengthen the quality management system within Medical Systems, net profit increased 70.9 % to SEK 253 M. · Earnings per share were a negative SEK 1.39 (0.76). · EBITA before restructuring costs declined 15.4% to SEK 670 M (792). First quarter of 2014 Order intake The Group’s order intake grew 0.3% organically during the first quarter of the year. The order intake for Medical Systems, which reported a highly satisfactory order intake in the year-earlier period, declined organically by 3.4%. Adjusted for delivery disruptions that impacted the Cardiovascular division during the quarter and were previously announced, the order intake for Medical Systems increased marginally. The order intake for Extended Care increased 0.9% organically compared with a weak year-earlier period and the order intake for Infection Control amounted to 8.9% organically. The increase in demand in Western Europe noted during the latter part of last year was confirmed by the order intake for the first quarter, which rose 5% organically. In the North American market, the organic order intake increased 1.0%. Most of the delivery disruptions that impacted Medical Systems pertained to the North American market. With respect to the order intake for markets outside North America and Western Europe, the trend for the period was weak, particularly in the BRIC countries. Teleconference with CEO Johan Malmquist and CFO Ulf GrunanderApril 16, 2014 at 3:00 p.m. Swedish timeSweden: +46 (0) 8 5033 6538UK: +44 (0) 20 3427 1906US: +1 212 444 0481Code: 53 86 501

Elekta Nomination Committee’s proposed Board of Directors for 2014 Annual General Meeting

The Nomination Committee’s other proposals to the Annual General Meeting to be held on August 28, 2014 will be available from the company’s website in conjunction with the publication of the notice of the Annual General Meeting. The Nomination Committee prior to the 2014 Annual General Meeting comprises the following members: · Laurent Leksell (Chairman), appointed by the Leksell family for the family’s direct and indirect holdings and in his capacity as Chairman of the Board. · Åsa Nisell, appointed by Swedbank Robur Funds · Anders Oscarsson, appointed by AMF and AMF Funds · Peter Rudman, appointed by Nordea Funds · Erik Sjöström, appointed by Skandia · Caroline Leksell Cooke, co-opted member # # # For further information, please contact:Gert van Santen, Group Vice President Corporate Communications, Elekta ABTel: +31 653 561 242, e-mail: gert.vansanten@elekta.comTime zone: CET: Central European Time Johan Andersson, Director, Investor Relations, Elekta ABTel: +46 702 100 451, e-mail: johan.andersson@elekta.comTime zone: CET: Central European Time The above information is such that Elekta AB (publ) shall make public in accordance with the Securities Market Act and/or the Financial Instruments Trading Act. The information was published at 07:30 CET on April 17, 2014. About ElektaElekta is a human care company pioneering significant innovations and clinical solutions for treating cancer and brain disorders. The company develops sophisticated, state-of-the-art tools and treatment planning systems for radiation therapy, radiosurgery and brachytherapy, as well as workflow enhancing software systems across the spectrum of cancer care. Stretching the boundaries of science and technology, providing intelligent and resource-efficient solutions that offer confidence to both health care providers and patients, Elekta aims to improve, prolong and even save patient lives. Today, Elekta solutions in oncology and neurosurgery are used in over 6,000 hospitals worldwide. Elekta employs around 3,500 employees globally. The corporate headquarters is located in Stockholm, Sweden, and the company is listed on the Nordic Exchange under the ticker STO:EKTAB. Website: www.elekta.com.

Tele2 AB: First Quarter 2014 Result Presentation

Tele2 AB will announce its financial results for Q1 2014 at 07:00 am CEST (06:00 am BST/01:00 am EDT) on Friday, April 25, 2014. Tele2 will host a presentation with the possibility to join through a conference call, for the global financial community at 10:00 am CEST (09:00 am BST/04:00 am EDT) on Friday, April 25, 2014. The presentation will be held in English and also made available as an audiocast on Tele2’s website: www.tele2.com. Dial-in information: To ensure that you are connected to the conference call, please dial in a few minutes before the start of the conference call to register your attendance. Dial-in numbers: Sweden: +46 8 505 564 74 UK: +44 203 364 5374 US: +1 855 753 2230 Contacts Lars Torstensson, EVP Corporate Communication, Telephone: +46 702 73 48 79 Viktor Wallström, Press Inquiries, +46 703 63 53 27 TELE2 IS ONE OF EUROPE'S FASTEST GROWING TELECOM OPERATORS, ALWAYS PROVIDING CUSTOMERS WHAT THEY NEED FOR LESS. We have 15 million customers in 10 countries. Tele2 offers mobile services, fixed broadband and telephony, data network services, cable TV and content services. Ever since Jan Stenbeck founded the company in 1993, it has been a tough challenger to the former government monopolies and other established providers. Tele2 has been listed on the NASDAQ OMX Stockholm since 1996. In 2012, we had net sales of SEK 31 billion and reported an operating profit (EBITDA) of SEK 6 billion

Blue Canyon Holdings’ comments on Meltwater’s press release

The offer from Blue Canyon Holdings AB (“Blue Canyon Holdings”), controlled by GTCR Investment X AIV Ltd., to the shareholders of Cision AB (publ) (“Cision”) expires on 22 April 2014 (the “Offer”). Blue Canyon Holdings offers SEK 61 in cash per share in Cision. In relation to Meltwater Drive Sverige AB’s (“Meltwater”) press release dated yesterday, 16 April 2014, Blue Canyon Holdings advises the shareholders of Cision of the following: · The Swedish Securities Council (Sw. Aktiemarknadsnämnden) has in its statement no. 2014:16 (available at www.aktiemarknadsnamnden.se) confirmed that Blue Canyon Holdings has not acted in breach of best market practice on the Swedish stock market; · It is Blue Canyon Holdings’ firm view that it has complied with applicable laws and the provisions of NASDAQ OMX Stockholm’s Rules concerning Takeover Bids on the Stock Market, including the policies and practices established by the Swedish Securities Council, in connection with its offer; · Blue Canyon Holdings furthermore confirms that the Stockholm District Court (Sw. Stockholms Tingsrätt) on 4 April 2014 issued an injunction against Fairford Holdings Finance AB, Cyril Acquisition AB, Lannebo Fonder and Accendo Capital SICAV-SIF, pursuant to their irrevocable undertakings with Blue Canyon Holdings, inter alia, prohibiting them to sell their shares in Cision other than pursuant to Blue Canyon Holdings’ offer; and · Meltwater’s offer is conditioned upon a number of items, including an acceptance level of at least 70 per cent. Blue Canyon Holdings owns shares representing 63.4 per cent of the shares and votes in Cision and will not tender its shares into Meltwater’s offer. As a result hereof, the acceptance level condition for Meltwater’s offer cannot be fulfilled. Blue Canyon Holding’s offer expires on Tuesday 22 April 2014. Duly completed acceptance forms shall be delivered or mailed and be received by SEB Emissioner no later than 17.00 (CET) on 22 April 2014. As Blue Canyon Holding’s offer is unconditional, shareholders do not have the right to withdraw given acceptances. Settlement is expected to begin around 30 April 2014. Information about the OfferFor information about Blue Canyon Holding’s offer, please see www.bluecanyon.se. Further informationFor media questions, please contact:Eileen RochfordPhone: +1 312.953.3305E-mail: eileenr@theharbingergroup.com This press release was submitted for publication on 17 April 2014 at 08:15 (CET). Important noticeThis is a translation of the original Swedish language press release. In the event of discrepancies, the original Swedish wording shall prevail. Offer restrictionsThe Offer is not being made to persons whose participation in the Offer requires that any additional offer document is prepared or registration effected or that any other measures are taken in addition to those required under Swedish law. This press release and any documentation relating to the Offer are not being published in or distributed to or into and must not be mailed or otherwise distributed or sent in or into any country in which the distribution or offering would require any such additional measures to be taken or would be in conflict with any law or regulation in such country. Any such action will not be permitted or sanctioned by Blue Canyon Holdings. Any purported acceptance of the Offer resulting directly or indirectly from a violation of these restrictions may be disregarded. The Offer is not being made, directly or indirectly, in or into Australia, Canada, Hong Kong, Japan, New Zealand or South Africa by use of mail or any other means or instrumentality (including, without limitation, facsimile transmission, electronic mail, telex, telephone and the Internet) of interstate or foreign commerce, or of any facility of national security exchange, of Australia, Canada, Hong Kong, Japan, New Zealand or South Africa, and the Offer cannot be accepted by any such use, means, instrumentality or facility of, or from within, Australia, Canada, Hong Kong, Japan, New Zealand or South Africa. Accordingly, this press release and any documentation relating to the Offer are not being and should not be sent, mailed or otherwise distributed or forwarded in or into Australia, Canada, Hong Kong, Japan, New Zealand or South Africa. Blue Canyon Holdings will not deliver any consideration under the Offer into Australia, Canada, Hong Kong, Japan, New Zealand or South Africa. This press release is not being, and must not be, sent to shareholders with registered addresses in Australia, Canada, Hong Kong, Japan, New Zealand or South Africa. Banks, brokers, dealers and other nominees holding shares for persons in Australia, Canada, Hong Kong, Japan, New Zealand or South Africa must not forward this press release or any other document received in connection with the Offer to such persons. Statements in this press release relating to future status or circumstances, including statements regarding future performance, growth and other trend projections and the other benefits of the Offer, are forward-looking statements. These statements may generally, but not always, be identified by the use of words such as “anticipates”, “intends”, “expects”, “believes”, or similar expressions. By their nature, forward-looking statements involve risk and uncertainty because they relate to events and depend on circumstances that will occur in the future. There can be no assurance that actual results will not differ materially from those expressed or implied by these forward-looking statements due to many factors, many of which are outside the control of Blue Canyon Holdings and Cision. Any such forward-looking statements speak only as of the date on which they are made and Blue Canyon Holdings has no obligation (and undertakes no such obligation) to update or revise any of them, whether as a result of new information, future events or otherwise, except for in accordance with applicable laws and regulations. Special notice to shareholders in the United StatesThe Offer described in this announcement is subject to the laws of Sweden. It is important for US securities holders to be aware that this document is subject to disclosure and takeover laws and regulations in Sweden that are different from those in the United States. As applicable, Blue Canyon Holdings will comply with Regulation 14E under the US Securities Exchange Act of 1934, as amended (“Exchange Act”) in connection with the Offer. The Offer is being treated in the United States as one to which the “Tier II” exemption mentioned in Rule 14d-1(d) under the Exchange Act is applicable. Pursuant to an exemption from Rule 14e-5 under the Exchange Act, Blue Canyon Holdings and certain of its Representatives may, from time to time, purchase or make arrangements to purchase shares outside the Offer from the time the Offer was announced until the expiration of the acceptance period of the Offer, including purchases in the open market at prevailing prices or in private transactions at negotiated prices, in each case, outside of the United States and to the extent permitted under the applicable Swedish laws and regulations. Any such purchases will not be made at prices higher than the price of the Offer provided in this announcement unless the price of the Offer is increased accordingly. Any future purchases will be made in accordance with applicable laws, rules and regulations. Any such purchases of shares will be disclosed to the extent required by Swedish law or rules or regulations and, if so disclosed, will also be disclosed in the US. NEITHER THE UNITED STATES SECURITIES AND EXCHANGE COMMISSION NOR ANY U.S. STATE SECURITIES COMMISSION OR REGULATORY AUTHORITY HAS APPROVED OR DISAPPROVED OF THIS OFFER, PASSED UPON THE FAIRNESS OR MERITS OF THIS ANNOUNCEMENT OR DETERMINED WHETHER THIS ANNOUNCEMENT IS ACCURATE OR COMPLETE. ANY REPRESENTATION TO THE CONTRARY IS A CRIMINAL OFFENSE IN THE UNITED STATES.

Interim report January – March 2014

·Net sales increased by 70% to 64.9 (38.1) MSEK ·Net profit after financial items increased to 3.6 (0.1) MSEK(including non-recurring costs associated with the acquisition of AP&C of 6 MSEK) ·Earnings per share amounted to 0.20 (0.01) MSEK ·Cash at the end of the period 368.1 (38.3) MSEK ·Order intake amounted to 6 (6) systems, and 7(4) systems were delivered in the period. ·The order book contained 11 (12) systems by the end of the period ·The acquisition of the metal powder manufacturer AP&C was completed on February 11. Significant events after the end of March: ·Two EBM system orders beginning of April Telephone conference with CEO Magnus René and CFO Johan Brandt April 17, 2014 at 2.00 p.m. (CET) SE: +46 8 505 982 61UK: +44 2 031 940 554US: +1 855 716 158 9 Link to presentation: http://event.onlineseminarsolutions.com/r.htm?e=782857&s=1&k=9B56BCCA7BBBB5AD6F347F6B395EE002 Increased sales and improved earnings For the first quarter we report a 70% increase in sales compared to the first quarter in 2013 and a significantly improved result. Trailing twelve month sales amounts to 226.2 MSEK and earnings amount to 18.9 MSEK. The result includes non-recurring costs in the first quarter 2014 associated with the acquisition of AP&C of 6 MSEK. The order intake during the period amounts to 6 systems and the order book as of today comprises 13 systems. Acquisition of AP&C In February we acquired the powder producer AP&C from Raymor Industries in Canada. AP&C is a leading manufacturer of high quality metal powder and supplier of titanium powder to Arcam since 2006. Titanium powder is an important part of our offering and with this acquisition we have secured access to the best technology for the production of high quality metal powder for our customers. The acquisition is fully in line with our growth strategy and complements our EBM technology and product portfolio. The acquisition was completed on February 11, and is consolidated from this date. AP&C´s share of group sales in the first quarter amounts to 3.5 MSEK after group eliminations. Business status We received 6 new orders during the quarter and we see a continued strong demand, particularly in Asia. The sales of our new large system, Arcam Q20, gains momentum and we have received 4 system orders. Arcam Q20 is planned for delivery to the first customers during the second quarter.  The work to industrialize our technology with the major players within the aerospace and implant industries continue and we can now see good opportunities for volume orders during the year. At the same time, we see that the growing interest and knowledge in Additive Manufacturing and 3D printing creates interest within new segments. This may long term give opportunities for broadening of our product applications. Of the 7 systems that were delivered during the first quarter the majority went to customers within the implant or the aerospace industry. The cooperation with DiSanto is progressing with agreements with customers for which DiSanto is manufacturing products. Growth – organic and through acquisition In addition to the acquisition of AP&C we are in rapid organic growth. We thus continue to recruit qualified employees in order to meet the expectations from our customers. During the quarter we have strengthened our service office in China and the support organization in Sweden. Through the acquisition of AP&C and through recruitment the number of employees has increased from 55 to 109 since March 2013. An order book of 13 systems, increasing aftermarket sales and a positive business situation lays a solid foundation for a continued strong growth in 2014.  Mölndal, April 17, 2014 Magnus René, CEO The above information has been made public in accordance with the Securities Market Act and/or the Financial Instruments Trading Act. The information was published on April 17, 2014 at 08.30 (CET).

NeuroVive presents medical breakthrough in cellular energy regulation

In simplified terms, the mitochondria can be considered as the energy factory of cells. There is currently scientific data indicating that many medical conditions, from chronic diseases to acute conditions affecting the heart and brain, are linked to their function. Succinic acid is a central component in energy production. This compound is involved in many pathogenic changes to energy production, which means that adding succinic acid can restore energy production. However, succinic acid is normally unable to transit the cell wall independently. NeuroVive’s and Selcia’s researchers have resolved this problem by altering succinic acid in various ways, with the result that the compound is able to transit the cell wall and then be freed up and utilized in mitochondrial energy production. Therapy areas and current development workThe new drug candidates may potentially be used to prevent or treat primary or secondary mitochondrial conditions and restore normal function. This means that if current development work is successful, they may be suitable to treat a large number of rare genetic conditions, as well as more general disorders where there is an increased need for energy. This dual application extends the potential for this new class of pharmaceutical. These new experimental drugs are currently undergoing formulation work. Their efficacy and potential adverse events must be examined in animal studies before they can be trialed on humans. The first major validation study on animals will be conducted in 2014. New medical analysis method for mitochondrial function in human cellsNeuroVive’s research team has also developed a medical analysis method for energy regulation in human cells that enables the study of molecules and pharmaceuticals that can directly increase or decrease energy production. This method, called ToxPhos®, has the potential for future use to support the diagnosis of mitochondrial disease and medical conditions. The method, although not used to produce the ‘Amber’ compounds, was central in the screening process of the energy-regulating experimental drugs and is the foundation for the development of several preclinical models for mitochondrial conditions. The patent application for this method was also published in the WIPO patent database on 10 April. ”Research into mitochondrial medicine in recent years has demonstrated that far more diseases and medical conditions may potentially be sourced from mitochondrial defects than previously believed. That’s why it was a natural move for us to start developing pharmaceuticals that not only protect the mitochondria in cell damage, but also offer the potential for cells to produce normal amounts of energy in injury and disease. These new experimental drugs that we’re developing may potentially be used as emergency treatment in cellular energy crisis in children with congenital limitations to energy production and, potentially, for other conditions where raised energy production counters the course of diseases. We’re really proud to be able to present the underlying scientific discoveries at this symposium in June,” commented Eskil Elmér, NeuroVive’s CSO. “The new experimental drugs have the potential to address a market worth billions of kronor and a substantial medical need in the treatment of rare diseases that affect the mitochondria. This application has great potential to secure orphan drug designation, which means a fairly speedy process prior to market launch and a long period of market exclusivity. These diseases usually affect children, which makes it extra urgent to start designing a suitable formulation and begin preparation of preclinical safety testing required before experimental drugs can be administered to patients in clinical trials,” continued Mikael Brönnegård, NeuroVive’s CEO. Presentation at an international symposium in JuneThese new experimental drugs and the underlying scientific discoveries, including the new medical analysis method ToxPhos®, will be presented by NeuroVive’s researchers at the United Mitochondrial Disease Foundation Symposium in Pittsburgh on June 4-7. There’s more information on the conference at www.umdf.org. About NeuroViveNeuroVive Pharmaceutical AB (publ), a leading mitochondrial medicine company, is developing a portfolio of products to treat acute cardiovascular and neurological conditions through mitochondrial protection. These medical conditions are characterized by a pressing medical need and have no approved pharmaceutical treatment options at present. NeuroVive’s products CicloMulsion® (heart attack) and NeuroSTAT® (traumatic brain injury) are currently being evaluated in phase III and phase II studies, respectively. NeuroVive’s research programs also include products for the treatment of anti-viral indications (Hepatitis B/C), brain cell injury in stroke patients, and drug candidates for cellular protection and treating mitochondria-related energy regulation diseases. NeuroVive’s shares are listed on NASDAQ OMX, Stockholm, Sweden. Current status of NeuroVive’s products CicloMulsion®NeuroVive’s product CicloMulsion® is the first cyclophilin inhibitor developed for treating reperfusion injury. The product’s potential for treatment of myocardial infarction is currently being evaluated in a clinical phase III study. The final participant of a total of 972 patients was enrolled on 16 February 2014. The results of this study are scheduled for presentation in 2015 after a one-year follow-up is completed on all patients and study data has been compiled. NeuroSTAT®NeuroVive is developing NeuroSTAT® for treating patients with severe traumatic brain injury (TBI). NeuroSTAT® is currently being evaluated in a clinical phase IIa study at Rigshospitalet, Copenhagen. The study is focusing on safety and pharmacokinetics, and 5 of a planned 20 patients have been enrolled. The design and planning work for a phase III study has commenced. The company has obtained orphan drug designation for NeuroSTAT® for moderate to severe cranial injury in the US and EU. Orphan drug designation confers market exclusivity for 7 years in the US and 10 years in the EU from the date when the company secures marketing authorization. NVP018The recently acquired cyclophilin inhibitors are part of a family of molecules called Sangamides, and based on a new and unique chemical platform of what are known as polyketides. NVP018 is NeuroVive’s primary drug candidate in the company’s new portfolio of potent cyclophilin inhibitors. It has undergone extensive preclinical development and has been developed for treating hepatitis B/C. This product demonstrates potent efficacy against virus replication and has a positive safety and pharmacokinetic profile. Cyclophilin inhibitors have the potential for broad-based application, and NeuroVive is also currently evaluating NVP018’s potential against other viral indications. Other productsMore information on all products developed by NeuroVive is available at www.neurovive.se/index.php/en/research-development/our-products For media and investor relations questions, please contact: Ingmar Rentzhog, Laika Consulting, tel: +46 (0)46 275 62 21 or ir@neurovive.seIt is also possible to arrange an interview with NeuroVive’s CEO Mikael Brönnegård via the contact above. NeuroVive Pharmaceutical AB (publ)Medicon Village, SE-223 81 Lund, SwedenTel: +46 (0)46 275 62 20 (switchboard), Fax: + 46 (0)46 888 83 48, info@neurovive.se, www.neurovive.se NeuroVive Pharmaceutical AB (publ) is required to publish the information in this news release under The Swedish Securities Market Act. The information was submitted for publication on 17 April 2014, at 8:45 a.m. CET.

AAK’s Annual Report 2013 and AAK Report 2013 are published

AAK’s Annual Report 2013 and AAK Report 2013 have been published and are available in English and Swedish at the company’s home page, www.aak.com. The printed versions of AAK Annual Report 2013 and AAK Report 2013 will be distributed by mail to shareholders and other stakeholders, commencing April 17, 2014. For further information, please contact:Anders ByströmDirector External Accounting & Investor RelationsPhone: +46 40 627 83 32Mobile: +46 709 88 56 13 The information is that which AarhusKarlshamn AB (publ) is obliged to publish under the provisions of the Stock Exchange and Clearing Operations Act and/or the Trading in Financial Instruments Act. The information was released to the media for publication on April 17, 2014 at 9 am CET. AarhusKarlshamn (AAK) is one of the world’s leading producers of high value-added speciality vegetable oils and fats solutions. These oils and fats solutions are characterized by a high level of technological content and innovation. AAK`s solutions are used as substitute for butter-fat and cocoa butter, trans-free and low saturated solutions but also addressing other needs of our customers. AAK has production facilities in Denmark, Mexico, the Netherlands, Sweden, Great Britain, Uruguay and the US. Further AAK has also toll manufacturing operations in Russia and Malaysia. The company is organized in three Business Areas; Food Ingredients, Chocolate and Confectionery Fats and Technical Products & Feed. AAK’s shares are traded on the NASDAQ OMX, Stockholm, within the Large Cap segment. Further information on AAK can be found on the company’s website www.aak.com.

Tire modelling guru Professor Pacejka pays a visit to Cruden

AMSTERDAM, The Netherlands – Renowned vehicle system and tyre dynamics expert, Professor Hans Bastiann Pacejka (80), paid a special visit to Cruden in April. The Professor emeritus at Delft University of Technology in Delft (Netherlands) drove a few laps of the Zandvoort circuit in a GT3 Porsche model developed by Cruden, on one of the company’s 6-DOF Hexatech motion simulators. Despite being the name behind the ‘magic formula’ which defines the tire models relied upon by vehicle dynamics and simulation engineers globally for the past 20 years, Professor Pacejka has rarely driven vehicle simulators. He was tempted to try out the Cruden simulator at the invitation of two of his former students, Cruden’s CEO Maarten van Donselaar and senior modeling and simulation engineer, Edwin de Vries. De Vries was assistant professor to Professor Pacejka between 1994 and 1998 where the two co-developed the Delft motorcycle tire model. He commented, “In the simulation world, this is the equivalent of a visit from royalty. We think the delight was two-way as Professor Pacejka was very happy to see his work still alive and kicking and being used for the benefit of motorsport and automotive customers all over the world. He particularly liked our so-called ‘Pacejka-player’ that we use to visualize the effect of parameter changes on tire force response, as part of our Racer Pro simulator software. He definitely wanted to have this software.”  Pacejka tire models are widely used in professional vehicle dynamics simulations, and racing car games, as they are accurate and easy to program. They pose a very limited demand on computational power so that vehicle model driving runs easily in real-time. ## About Cruden Cruden is the world’s leading designer and manufacturer of professional, interactive, motion-based racing simulators. The company develops the most high tech, realistic and accurate professional equipment for the top levels of international motorsport, including Formula 1, as well as vehicle manufacturers and their suppliers. The same package is then made available to the global attractions market and to private individuals to create a motorsport experience which simply does not compare with ‘games’ machines on the market. Cruden’s heritage is in the development of professional simulators for the aerospace, marine and automotive industries. Originating from Fokker Aircraft Company, the company was FCS Racing Simulation before becoming Cruden in 2006. www.cruden.com Press Enquiries Claire Dumbreck, Unit 4, Manor Farm Offices, Northend Road, Fenny Compton, Warwickshire, UK, CV47 2YY. +44 (0)1295 770602 / +44 (0) 7768 773857 c.dumbreck@cruden.com (c.dumbreck@cruden.com)

Minnesota Launches Its Largest-Ever Marketing Effort to Boost Tourism

ST. PAUL, Minn. (April 17, 2014) – Today at the Minnesota State Capitol, Governor Mark Dayton and Explore Minnesota Tourism Director John Edman launched the state’s all-new travel marketing campaign, designed to encourage travelers to choose Minnesota as their next vacation destination. The marketing campaign, themed Only in Minnesota, promotes Minnesota as a one-of-a-kind Midwest travel destination. This year’s effort, which will reach audiences in 14 states and provinces, is the largest travel marketing campaign in the state’s history. “Every dollar we invest in promoting Minnesota tourism brings another $84 of consumer spending into our state’s economy – supporting Minnesota’s vitally important hospitality industry,” said Governor Dayton. "That is why I worked with the Legislature last year to increase Explore Minnesota Tourism’s budget by over 65 percent.” Promoting what is unique and special about our state is what the Only in Minnesota travel marketing campaign is all about – celebrating specific travel adventures, activities, and attractions that can only be found in Minnesota. “Minnesota is an exciting state; there are numerous diverse opportunities for travelers and tourism stakeholders alike to rally and share authentic Minnesota travel experiences,” said John Edman, Director of Explore Minnesota Tourism. “This new campaign is a movement that will highlight unique Minnesota attractions and engage consumers in conversation about Minnesota travel. This cutting-edge campaign allows our state to be more competitive, and grow tourism across Minnesota.” Only in Minnesota: Promoting What Makes Our State Special Research shows that travelers want to experience new and unique things when they travel. That is why the Only in Minnesota campaign features Minnesota’s distinct outdoor adventures, cultural experiences, and unique landmarks – differentiating Minnesota from other Midwest travel destinations. From camping and hiking in Minnesota’s great outdoors, to enjoying the nightlife of the big city, to experiencing the charm of a local restaurant, this year’s advertisements set Minnesota apart. And in keeping with the Only in Minnesota theme, the campaign incorporates homegrown Minnesota talent, including local musicians, and writers. To be part of the campaign, and join the conversation, you can watch all four of the new TV ads on YouTube (https://www.youtube.com/user/ExploreMinnesota), and share your photos and unique Minnesota travel experiences on Twitter, Facebook, Instagram, and Pinterest by using the official campaign hashtag #OnlyinMN. Minnesota’s Biggest Travel Marketing Campaign Ever With an all-new series of television, outdoor, and digital ads, and a strong, user-driven social media movement that will engage travelers, residents, businesses, and visitors bureaus across the state, the Only in Minnesota campaign is comprehensive and far-reaching. With ad buys of more than $3.7 million over the next three months alone, this year’s effort is more than double in size and scope than last year’s travel marketing campaign. More than $11 million in additional funding provided over the current biennium by the Legislature and Governor Dayton has allowed Explore Minnesota Tourism to expand its overall marketing impact this year with enhanced reach across all four advertising seasons (spring, summer, fall, and winter). That additional funding has also expanded the reach of the Only in Minnesota campaign into target markets in six new states and two new provinces across the region, including: Illinois, Kansas, Missouri, Colorado, Montana, Wyoming, Manitoba and Saskatchewan. Explore Minnesota Tourism will also target new niche markets this year, increase international marketing, and develop additional marketing partnerships to enhance the impact of the state’s travel marketing campaign. The new campaign was created by advertising agency Colle+McVoy. A Better Website In keeping with Governor Mark Dayton’s Plain Language Initiative, and in the effort to make it easier for travelers to find information about vacation destinations and activities in Minnesota, Explore Minnesota Tourism this week launched a new and improved website. The previous website was not as compatible with mobile devices. “Over the last several years, we have seen tremendous growth in visitor site traffic through mobile devices,” said Edman. “We need to meet travelers where they are, and that means being accessible on mobile devices and social media. Our new responsive-design website offers travelers the information and user experiences they need to identify and learn about Minnesota’s many unique assets, and more easily make their travel plans.” Explore Minnesota Tourism’s redesigned, visually-enhanced website (www.exploreminnesota.com) offers a more user-friendly, interactive experience for travelers. Developed by BarkleyREI, the new website will be highly accessible via mobile devices and showcases picturesque imagery, travel articles and advanced search functions to lure travelers to Minnesota. To make travel planning even easier, the new website features a live chat function where travelers can ask questions about Minnesota and get advice for charting out their next visit to our state. # # #